Download Home • Canadian Association of Radiation Oncology

CARO2012
Targeting
Biology
OTTAWA September 12–15
caro-acro.ca
CARO 2012 ANNUAL SCIENTIFIC MEETING
ACRO 2012 RÉUNION SCIENTIFIQUE ANNUELLE
SPONSORS
EXHIBITORS
PLATINUM
3M Canada
Abbott
Accuray
AstraZeneca
Best Medical Canada
Brainlab
Carl Zeiss Canada
CARO • CROF
CSP Medical
BRONZE
Elekta
Ferring Pharmaceuticals
GE Healthcare
IsoAid
Janssen
Login
MIM Software Inc.
Orfit Industries America
HEALTH AND WELLNESS
Paladin
Philips Healthcare
Varian
SEPTEMBER 12-15, 2012• OTTAWA, ON
OTTAWA CONVENTION CENTRE
CARO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
TABLE OF CONTENTS
Letter from the Minister
i
Letters from the President, Chair and Local Chair
ii
Accreditationx
WEDNESDAY, SEPTEMBER 12, 2012
1
Resident Refresher Course 1
Keynote: Drug-Radiotherapy Interactions to Improve Cure: Present and Future1
Molecular Targeted Therapies Integrated into Radiation Oncology
2
Keynote: D
esign and Conduct of Trials Combining Radiotherapy
and Targeted Therapeutics
2
2
HEENT and CNS: Abstracts 1–4
Lung and Breast: Abstracts 5–83
Biomarkers: Abstracts 9–113
GYNE, GI and GU: Abstracts 12–143
Novel Biomarkers and Radiomodifiers: from Concept to Clinical Trail Design Workshop 4
THURSDAY, SEPTEMBER 13, 2012
5
CARO Presidential Address
5
CARO LECTURE: CHANGING DEMOGRAPHICS OF HEAD AND NECK CARCINOMA5
Resident Competition: Abstracts 15–245
Theme Symposium: Debate
6
Poster Preview 1: Abstracts 25–74
6
Poster Preview 2: Abstracts 75–12410
FRIDAY SEPTEMBER 14, 2012
14
CROF Fun Run/Walk
14
Gordon Richards Lecture: NEXT-GEN RADIATION ONCOLOGY14
Poster Viewing
14
Canadian Brachytherapy Group Session: Abstracts 125–12814
CBG Keynote: HDR Monotherapy for Prostate Cancer:
Success without External Beam Radiotherapy?14
Workshops 1 to 5
15
Oral Session 1: CLINICAL — BREAST AND HEAD AND NECK Abstracts 129–137
16
Oral Session 2: CLINICAL — PROSTATE Abstracts 138–146
17
Oral Session 3: TECHNOLOGY Abstracts 147–15518
SATURDAY SEPTEMBER 15, 2012
19
Workshops 1 to 4
19
Canadian Brachytherapy Group Session: Abstracts 156–161
20
Oral Session 4: EDUCATION AND SURVIVORSHIP Abstracts 162–170
20
Oral Session 5: CLINICAL — LUNG AND CNS Abstracts 171–180
21
CARO-ESTRO Symposium: Frontiers in Radiation Biology: The Next Decade
22
People’s Choice: Abstracts 181–185
22
POSTER ABSTRACTS Abstracts 186–257
24
BIENVENUE Á ACRO 2012
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
As Minister of Health, I wish to extend greetings to the participants of the Annual Scientific
Meeting of the Canadian Association of Radiation Oncology. This year’s theme, “Targeting
Biology,” will address the impact of biological markers in the treatment of cancer patients by
radiation oncologists and radiobiologists.
The Government of Canada commends the vital role played by experts in radiation oncology in
the proper diagnosis and treatment of patients. From a patient’s perspective, there is comfort in
knowing that Canada’s oncology researchers, scientists and clinicians are global leaders in the
development, testing and implementation of new techniques and strategies to treat cancer.
The contribution of Canada’s dedicated experts in radiation oncology is felt every day. The
Government of Canada works with provinces, territories and stakeholders to support the adequate
supply of health care professionals, including those who treat cancer, so that all Canadians have
access to the health services they need.
Through programs such as the Pan-Canadian Health Human Resource Strategy and the
Internationally Educated Health Professionals Initiative, Health Canada is committed to securing
and maintaining an optimal health workforce in Canada and investing in overall health care
renewal.
The federal government also works with provincial and territorial governments to improve the
health system throughout the country, as well as with non-government organizations such as the
Canadian Association of Radiation Oncology, whose expertise and commitment to excellence
helps us develop effective health policies.
I would like to thank the Canadian Association of Radiation Oncology for organizing this event. I
wish you all a very successful conference.
WELCOME TO CARO 2012
i
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
ANDREA BEZJAK
LETTER FROM
THE PRESIDENT
Dear Colleagues,
Welcome to Ottawa and the 26th Annual
Scientific Meeting (ASM) of the Canadian
Association of Radiation Oncology (CARO)!
It is going to be another stellar combination
of learning about a variety of excellent
projects from across Canada, touching on all
aspects of radiation oncology practice, while
connecting with friends and getting to know
colleagues better
In a survey of CARO members we did last
fall, you strongly endorsed the valuable role
of CARO and its ASM and the academic,
practical and social aspects of our meeting
—something that goes beyond what ASTRO,
ESTRO or the myriad other meetings can
provide. We have listened to your comments
and suggestions in formulating our Strategic
Plan, you will hear more in my opening
remarks at the CARO Presidential Address
Thursday, September 13 in the morning, and
the CARO Annual General Meeting in the
afternoon of the same day.
The theme of this year’s CARO meeting
is Targeting Biology —a clever choice as
it integrates the two underpinnings of
our specialty— the concept of targeting
(identifying and focusing on the tumour
itself) and biology, that is, truly exploring and
understanding what is happening biologically
in the tumour, especially in response to
radiation.
WELCOME TO CARO 2012
Christina Parsons and her colleagues,
members of the ASM Program Committee
have developed an exciting agenda that has
several new features, more oral presentations,
an expanded poster session, and a record
number of high-profile international guest
speakers, including Dr Kian Ang as the CARO
Lecturer, Drs Kevin Camphausen from NCI,
Donal Hollywood and Anne Hansen Ree from
ESTRO, Mihai Ghilezan as the Brachytherapy
Keynote Lecturer and our own Fei-Fei Liu as
the Gordon Richards Lecturer.
Let’s not forget the social activities: the
Welcome Reception on Thursday, Dinner and
Awards Ceremony on Friday and the CROF
Run/Walk on Friday morning. It was such
fun last year – come and join us. Let’s see
who can challenge last year’s fastest runner,
David Palma, and last year’s biggest fundcontributor, Jackson Wu.
Please call, email or stop me in the hallways
to let me and other CARO Board members
know what else our society can do for you.
In the meantime, enjoy CARO 2012 and
Ottawa.
Fondly,
Andrea Bezjak
President, Canadian Association of Radiation Oncology
ii
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
CHRISTINA PARSONS
LETTER FROM
THE ASM CHAIR
Dear Colleagues,
On behalf of the CARO Annual Scientific
Meeting organizing committee, I would
like to invite you to attend the 26th CARO
Annual Scientific Meeting held September
12th-15th, 2012 in Ottawa, Ontario. As the
CARO community continues to embrace new
biological targets and a myriad of exciting
technologies, the ASM has established itself
as the premier venue to highlight Canadianled oncology research. The ASM provides
an opportunity to foster collaborative
relationships, professional development and
provides a forum for knowledge exchange.
To enhance your experience at the ASM,
the Organizing Committee has made some
modifications to the program. The CARO
Lecture and the jewel of the meeting, the
Resident’s competition, remain on Thursday
morning setting the tone for the following
days. The number of proffered presentations
has increased by decreasing the time
devoted to each paper. We have expanded
the opportunity to participate in the highly
rated small group interactive workshops by
repeating these on consecutive days. As well,
brachytherapy sessions will be staggered as
well, increasing registrants’ opportunity for
interaction with the speakers.
This year’s guest speakers, Drs. Kian Ang,
Fei-Fie Lui, Kevin Camphausen, Donal
Hollywood and Ann Hansen Ree will be
actively participating in workshops and
sessions throughout the meeting, providing
registrants increased exposure to these
international experts. A new initiative
WELCOME TO CARO 2012
highlighting the wealth of information
presented in the posters is the introduction
of Poster Preview sessions. We hope you
find these “rapid fire” sessions valuable.
As the grand finale, the People’s Choice
Plenary session will include presentations of
exemplary international and Canadian-led
research.
The Annual Scientific Meeting is the ‘flagship’
event of CARO, and the submission of over
270 abstracts in 2012 is a testament of the
interest in, and support of, the CARO ASM!
We hope that the variety of sessions including
oral presentations, workshops, a debate, case
presentations as well as the didactic lectures at
the 2012 ASM, will amplify your experience
at this meeting, and strengthen your resolve
to continue to support CARO. Building on
the past quarter century of successful CARO
ASM’s we cherish the past, celebrate the
present and look forward to future CARO
Annual Scientific Meetings as the stage
to present the burgeoning Canadian-led
oncology research.
“Coming together is a beginning, staying
together is progress and working together is
success.” —Henry Ford
Christina Aquino Parsons
Chair, CARO 2012
Annual Scientific Meeting Committee
iii
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
LAVAL GRIMARD
LETTER FROM
THE LOCAL CHAIR
ASM PLANNING COMMITTEE
Dear Colleagues,
Welcome to Ottawa for the 26th Annual
Scientific Meeting of CARO. This year,
the theme for our meeting is Targeting
Biology which will be also the topic of the
pre-conference symposium on Wednesday,
September 12. We have an exciting
scientific program which focuses on the
clinical aspects of our understanding of the
Biology of cancer.
attractions are the Parliament buildings,
Rideau Canal and Locks, National Gallery of
Canada, War Museum, Aviation and Space
Museum, Museum of Nature, Museum of
Civilization, Notre Dame Cathedral, and the
Byward Market. Fine dining in Ottawa is
both easy and difficult as the choice of fine
and diverse restaurants is overwhelming,
from reasonable to not so reasonable prices.
Metropolitan Ottawa is the fourth largest
city in Canada. Ottawa is a thriving
technology centre and a favorite tourism
destination with its many national
institutions, museums, parklands, extensive
bike paths and waterways, as well as historic
architecture. Languages spoken include
English (50%), French (32%) and a host of
other languages including Spanish, Italian,
Portuguese, Chinese and Arabic. Whether
your interest is culture, history or simply
natural outdoor attractions, Canada’s capital
region offers a unique combination of many
interests with 30 museums, 50 galleries and
theatres.
Most of all, mid-September in Ottawa is
typically a warm and pleasant weather
period with sunny days and cool nights.
You may want to add some vacation time to
complement our national annual meeting in
this destination of choice.
Friendly people are what makes Ottawa one
of the best places to live in North America!!
Mid-September is an ideal time to come
with the family and take a few extra days
to enjoy our nation’s capital. The main
WELCOME TO CARO 2012
From the Radiation Oncology community of
our nation’s capital, a warm welcome for our
exciting meeting, a few steps from Parliament
Hill with lectures, oral presentations, and
posters; and do not forget the CROF Friday
morning 5km Fun Run/Walk.
See you in Ottawa!
Laval Grimard
Local Chair, CARO 2012
Annual Scientific Meeting Committee
iv
CARO • ACRO RÉUNION SCIENTIFIQUE ANNUELLE
SEPTEMBER 12 – 15, Ottawa, ON
À titre de ministre de la Santé, je tiens à souhaiter la bienvenue à tous les participants à la réunion
scientifique annuelle de l’Association canadienne de radio-oncologie. Le thème de cette année,
Targeting Biology (Comment cibler la biologie), se penche sur les répercussions des marqueurs
biologiques dans le traitement par les radio-oncologues et les radiobiologistes des patients atteints
du cancer.
Le gouvernement du Canada reconnaît le rôle essentiel des radio-oncologues dans l’établissement
du diagnostic et le traitement appropriés des patients. Pour un patient, il est rassurant de savoir
que les chercheurs en oncologie, les scientifiques et les cliniciens sont des chefs de file mondiaux
dans la mise au point, l’essai et l’application de nouvelles techniques et stratégies pour traiter le
cancer.
La contribution quotidienne des experts du Canada en radio-oncologie ne passe pas inaperçue. Le
gouvernement du Canada collabore avec les gouvernements provinciaux et territoriaux et d’autres
intervenants afin qu’il y ait un nombre suffisant de professionnels de la santé, y compris de
spécialistes du cancer, pour que tous les Canadiens aient accès aux services de santé dont ils ont
besoin.
Au moyen de programmes tels que la Stratégie pancanadienne relative aux ressources humaines
en santé et l’Initiative relative aux professionnels de la santé diplômés à l’étranger, Santé Canada
s’est engagé à recruter et à maintenir en poste un effectif optimal en santé au Canada et à investir
dans le renouvellement global des soins de santé.
Le gouvernement fédéral collabore également avec les gouvernements provinciaux et territoriaux
afin d’améliorer le système de santé partout au pays. Nous travaillons également avec des
organisations non gouvernementales comme l’Association canadienne de radio-oncologie, dont
l’expertise et l’engagement envers l’excellence nous permettent d’élaborer des politiques
efficaces en matière de santé.
Je remercie l’Association canadienne de radio-oncologie d’avoir organisé cette activité. Je vous
souhaite une réunion des plus fructueuses.
1
BIENVENUE Á ACRO 2012
v
CARO • ACRO RÉUNION SCIENTIFIQUE ANNUELLE
SEPTEMBER 12 – 15, Ottawa, ON
ANDREA BEZJAK
LETTRE DU
PRÉSIDENT
Chers collègues,
Bienvenue à Ottawa et à la 26e Réunion
annuelle scientifique (RAS) de l’Association
canadienne de radio-oncologie (ACRO)!
Il s’agira certainement d’une autre
combinaison stellaire d’activités qui vous
permettront d’apprendre au sujet d›une
variété d’excellents projets partout au
Canada, examinant tous les aspects de la
pratique de la radio-oncologie, d’établir des
liens avec vos amis et d’apprendre à mieux
connaître vos collègues.
Dans le cadre d’un sondage réalisé auprès
des membres de l’ACRO à l’automne
dernier, vous avez fortement appuyé le
rôle de l’ACRO et de la RAS, et les aspects
universitaires, pratiques et sociaux de notre
réunion – un événement qui va bien audelà de ce que peuvent offrir les réunions
de l’ASTRO et de l’ESTRO ou tout autre
éventail de réunions. Nous avons tenu
compte de vos commentaires et suggestions
pour élaborer notre plan stratégique, et je
discuterai davantage de ce point dans le mot
d’ouverture que je prononcerai dans le cadre
du discours de la présidente de l’ACRO, qui
aura lieu le jeudi 13 septembre, au matin, et
à l’assemblée générale annuelle de l›ACRO,
qui aura lieu en après-midi, le même jour.
Cette année, le thème de la réunion de
l›ACRO est « Comment cibler la biologie »
– un choix intelligent comme il intègre
les deux piliers fondamentaux de notre
spécialité – le concept du ciblage (identifier
la tumeur et se concentrer sur celle-ci) et
la biologie, c›est-à-dire l›exploration et la
compréhension réelles de ce qui se produit
BIENVENUE Á ACRO 2012
dans la tumeur sur le plan biologique,
particulièrement en réponse à la radiation.
Christina Parsons et ses collègues, membres
du comité de programme de la RAS, ont
élaboré un ordre du jour stimulant contenant
bon nombre de nouvelles caractéristiques,
un plus grand nombre d›exposés, une séance
d›affichage élargie et un nombre record
de conférenciers internationaux de très
bonne réputation, dont les Drs Kian Ang,
conférencier de l’ACRO, Kevin Camphausen
du NCI, Donald Hollywood et Anne Hansen
Ree de l’ESTRO, Mihai Ghilezan, conférencier
d’honneur sur la curiethérapie, et Fei-Fei Liu,
qui donnera la conférence Gordon Richards.
N’oublions pas les activités sociales : la réception
d›accueil qui aura lieu le jeudi, le repas du soir et
la cérémonie de remise des prix qui auront lieu
le vendredi et la course/marche de la FCRO qui
aura lieu le vendredi matin. Nous nous sommes
tellement amusés l’an dernier – joignez-vous à
nous et voyons qui pourra lancer un défi à David
Palma, le coureur le plus rapide, et à Jackson
Wu, le plus important contributeur financier de
l’an dernier.
N’hésitez pas à me téléphoner ou à arrêter
dans les couloirs d’autres membres du conseil
de l’ACRO ou moi-même, afin de nous
indiquer ce que notre société peut faire de
plus pour vous. Entre-temps, profitez de la
réunion de 2012 de l›ACRO et d’Ottawa.
Sincèrement,
Andrea Bezjak
Présidente, Association canadienne de radio-oncologie
vi
CARO • ACRO RÉUNION SCIENTIFIQUE ANNUELLE
SEPTEMBER 12 – 15, Ottawa, ON
CHRISTINA PARSONS
LETTRE DU
PRÉSIDENTE, COMITÉ
DE PLANIFICATION DU CSA
Chers collègues,
Au nom du comité organisateur de la
Réunion scientifique annuelle de l’ACRO,
j’aimerais vous inviter à assister à la 26e
Réunion scientifique annuelle (RAS) de
l’ACRO qui aura lieu du 12 au 15 septembre
2012 à Ottawa, en Ontario. À mesure
que la communauté de l’ACRO continue
d’embrasser de nouvelles cibles biologiques
et une myriade de technologies innovantes,
la RSA est devenue le principal événement
pour faire valoir la recherche en oncologie
menée au Canada. Cette réunion constitue
l’occasion d’encourager un travail collaboratif
et le développement professionnel, et fait
office de tribune favorisant l’échange des
connaissances.
Afin d’approfondir votre expérience à la RAS,
le comité organisateur a apporté certaines
modifications au programme. La Conférence
de l’ACRO et le Concours des résidents, le
moment fort de la réunion, auront encore
lieu le jeudi matin et ouvriront la voie à
l’échange de connaissances qui se poursuivra
tout au long des jours suivants. Le nombre
de présentations a augmenté de sorte que
le temps alloué à chaque exposé s’est vu
diminuer. Nous avons élargi les possibilités
de participer aux ateliers interactifs en
petits groupes en offrant des reprises les
journées consécutives. De plus, les séances
de brachythérapie seront échelonnées pour
permettre aux participants d’interagir plus
facilement avec les conférenciers.
Les conférenciers invités de cette année,
les Drs Kian Ang, Fei-Fie Lui, Kevin
Camphausen, Donal Hollywood et Ann
Hansen Ree, participeront activement aux
BIENVENUE Á ACRO 2012
ateliers et aux séances tout au long de la
réunion, ce qui permettra aux participants
de mieux goûter aux propos de ces experts
internationaux. Une nouvelle initiative,
les séances de Présentation préliminaire
des affiches, vise à souligner la richesse
des informations présentées dans les
affiches. Nous espérons que ces séances de «
présentation éclair » vous seront utiles. Pour
clore en beauté, la séance plénière du Choix
populaire comprendra des présentations
de travaux de recherche internationaux et
canadiens exemplaires.
La RAS est l’événement phare de l’ACRO. La
soumission de plus de 270 résumés en 2012
témoigne de l’intérêt et du soutien portés à
cette réunion! Nous espérons que la variété
des séances (y compris les présentations
orales, les ateliers, le débat, les présentations
de cas et les conférences didactiques) offertes
lors de la RAS 2012 sauront accroître votre
expérience cette année et renforcer votre
soutien continu envers l’ACRO. Nous
célébrons un quart de siècle de réunions
annuelles scientifiques de l’ACRO couronnées
de succès et nous nous réjouissons que les
futures réunions scientifiques annuelles nous
permettront d’assister à l’essor de la recherche
en oncologie menée par les Canadiens.
« Se réunir est un début; rester ensemble est un
progrès; travailler ensemble est la réussite. »
­—Henry Ford
Christina Aquino Parsons
Présidente, Comité de planification du CSA
vii
CARO • ACRO RÉUNION SCIENTIFIQUE ANNUELLE
SEPTEMBER 12 – 15, Ottawa, ON
LAVAL GRIMARD
LETTRE DU
DE L’ANIMATEUR
LOCAL DE LA RSA
Chers collègues,
Bienvenue à Ottawa à l’occasion de la 26e
Réunion scientifique annuelle de l’ACRO.
Le thème de cette année est « Targeting
Biology » (Comment cibler la biologie)
qui sera également le sujet du symposium
préconférence prévu le mercredi 12
septembre. Nous avons un programme
scientifique intéressant qui se penchera sur les
aspects cliniques de notre compréhension de
la biologie du cancer.
Rideau et les écluses, le Musée des beauxarts du Canada, le Musée de la guerre, le
Musée de l’aviation et de l’espace, le Musée
de la nature, le Musée des civilisations, la
Cathédrale Notre-Dame et le marché By. Il
est à la fois facile et difficile de choisir un
restaurant gastronomique puisque le nombre
de restaurants raffinés et diversifiés est
incroyable, les prix étant de raisonnables à
plus coûteux.
L’Ottawa métropolitain est la quatrième
plus grande ville au Canada. Ottawa est un
technocentre prospère et une destination
touristique favorite grâce à ses institutions
nationales, ses musées, ses forêts-parcs, son
vaste réseau de pistes cyclables et ses voies
d’eau, ainsi que son architecture historique.
Les langues parlées sont l’anglais (50 pour
cent), le français (32 pour cent) et un éventail
d’autres langues comme l’espagnol, l’italien,
le portugais, le chinois et l’arabe. Que vous
ayez un intérêt pour la culture, l’histoire ou
simplement les attraits de la nature, la région
de la capitale nationale sait satisfaire de
nombreux intérêts grâce à 30 musées et 50
galeries et théâtres.
Plus particulièrement, la mi-septembre
à Ottawa est généralement une période
où le climat est chaud et agréable, les
jours ensoleillés et les nuits fraîches. Vous
pourriez songer à prendre quelques jours
supplémentaires de vacances et prolonger
votre séjour lors de notre réunion annuelle
nationale dans cette ville de choix.
La cordialité des habitants de la région font
d’Ottawa l’un des meilleurs endroits où
élire domicile en Amérique du Nord. La
mi-septembre est un moment idéal pour
y venir en famille et profiter de quelques
jours supplémentaires pour admirer notre
capitale nationale. Les principaux attraits
sont les immeubles du Parlement, le canal
BIENVENUE Á ACRO 2012
Au nom de la communauté de radio-oncologie
de notre capitale nationale, je vous souhaite
la plus chaleureuse bienvenue en vue de
notre réunion stimulante, qui aura lieu à
quelques pas de la Colline du Parlement et qui
comprendra des conférences, des exposés et
des affiches, sans oublier la balade centraide
de 5 km de la FCRO qui se tiendra le vendredi
matin.
Au plaisir de vous voir à Ottawa!
Laval Grimard
animateur local, Comité de planification
de la réunion scientifique annuelle
viii
CARO • ACRO ANNUAL SCIENTIFIC MEETING
CARO Board of Directors 2011-2013
Andrea Bezjak, President
Ross Halperin, President Elect (BC Director)
John Kim, Secretary/Treasurer (Ontario Director)
Naseer Ahmed, Prairies Director
Jeffrey Cao, Residents and Fellows Director
Matthew Parliament, Ex-Officio - Past President
Dorianne Rheaume, Ex Officio - Royal College Specialty
Committee Chair
David Roberge, Québec Director
Teri Stuckless, Eastern Provinces Director
Eric Vigneault, Québec Director
Annual Scientific Committee
Shahida Ahmed
Cynthia Araujo
Boris Bahoric
Robert Bristow
Holly Campbell
Jeffrey Cao
Susan Dallin O’Grady, CARO Office
Guila Delouya
William Foster
Laval Grimard, Local Organizing Chair
Mary Hooey, ASM Coordinator
Chandra Martens
Gerard Morton
Thierry Muanza
Shelley Murdock, CARO Office
Alia Norman
Jason Pantarotto
Christina Parsons, Chair
Tara Rosewall
Jessica Seguin, CARO Office
WELCOME TO CARO 2012
SEPTEMBER 12 – 15, Ottawa, ON
Jackson Wu
Guest Faculty
Kian Ang, CARO Lecturer
Glenn Bauman
Robert Bristow
Kevin Camphausen
Choan E
Mihai Ghilezan
Donal Hollywood
Wayne Kendal
Fei-Fei Liu, Gordon Richards Lecturer
Anne Hansen Ree
Richard Tsang
Woodrow Wells
ix
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
Objectives
The CARO 2012 Annual Scientific Meeting has been developed to provide an opportunity
for participants to interact with colleagues and experts in the field of radiation oncology and
radiobiology.
This meeting will allow participants to:
❚ review the impact of biological markers in the treatment of cancer patients.
❚ provide a platform highlighting Canadian initiated research in cancer care.
❚ provide an forum for international collaborative research in cancer care.
❚ provide an opportunity for professional development for members of the health care team
involved in cancer care.
Accreditation
Presentations
This event is an accredited group learning
activity under Section 1, as defined by the
Royal College of Physicians and Surgeons of
Canada for the maintenance of certification
program.
All oral presentations in this program contain
25% for interactivity.
❚ 90-minute presentations include 60-minute
talk, 30-minute question and answer period.
Accreditation has been approved for:
❚ Canadian Association of Medical
Radiation Technologists (CAMRT) ­–
up to 30.5 Category A Credits
❚ 60-minute presentations include 45-minute
talk, 15-minute question and answer period.
❚ 10-minute presentations include 7-minute
talk, 3-minutes question and answer period.
❚ Medical Dosimetrist Certification Board
(MDCB) – up to 29.5 units
Applications have been submitted to:
❚ University of Ottawa
WELCOME TO CARO 2012
x
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, OTTAWA, ON
Wednesday, September 12, 2012
PRECONFERENCE EVENTS Level 2
Resident Refresher Course Room 205
Facilitator: Shahida Ahmed
OBJECTIVES: Upon completion of this refresher course, attendees should be able to:
❚ review the principles of management of common cancers including lymphomas,
cancers of the central nervous system, head and neck region, esophagus/GE
junction, skin cancers and cervical cancers with emphasis on radiation treatment
planning;
❚ learn the impact of biological markers in the treatment of cancer.
7:00–8:00
Registration and Breakfast
8:00–8:10 Welcome
8:10–8:50
CNS MALIGNANCIES Glenn Bauman
8:50–9:30
SKIN CASES Woodrow Wells
9:30–10:10 ESOPHAGUS / GE JUNCTION Wayne Kendal
10:10–10:30 Break
10:30–11:10 HEAD & NECK CASES Khalil Sultanem
11:10–11:50 LYMPHOMAS Richard Tsang
11:50–1:00 Lunch
12:00–1:00 RESIDENT AND FELLOW COMMITTEE MEETING Room 203
Keynote
DRUG-RADIOTHERAPY INTERACTIONS TO IMPROVE CURE:
PRESENT AND FUTURE Kevin Camphausen
2:00–2:40
CA CERVIX Choan E
2:40–3:00
Break
3:00–4:30
CAREER COUNSELING Department Heads
4:30–4:40
Closing Remarks and Evaluations Shahida Ahmed
1:00–2:00
WEDNESDAY September 12 CARO 2012 PRECONFERENCE
1
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, OTTAWA, ON
Molecular Targeted Therapies
Integrated into Radiation Oncology Room 207
Facilitators: Robert Bristow, Thierry Muanza
OBJECTIVES: At the end of this Pre-Conference, attendees should be able to:
❚ describe the interactions of molecular targeted agents and radiotherapy;
❚ describe the relevant biomarkers for efficacy and toxicity of molecular combined
modality therapy;
❚ apply these concepts to cases commonly presenting in radiotherapy clinics;
❚ understand the use of genomic and proteomic discovery approaches in biomarker
development for oncologic use.
7:30–8:00
Registration and Breakfast
8:00–8:10
WELCOME AND INTRODUCTION Robert Bristow
K
eynote
DESIGN AND CONDUCT OF TRIALS COMBINING RADIOTHERAPY
AND TARGETED THERAPEUTICS Anne Hansen Ree
8:10–9:10
9:10–9:25
Head and Neck and Central Nervous System Cancers
KEY QUESTIONS AND ILLUSTRATIVE CASES
Moderators: Fei-Fei Liu, Thierry Muanza
9:25–10:10
ABSTRACTS – HEENT AND CNS
9:25–9:35
1
ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS AND LATE SALIVARY GLAND TOXICITY
FOLLOWING INTENSITY MODULATED RADIOTHERAPY (IMRT) Lisa Capelle1, Sunita Ghosh1,
Sana Vahidy2, Brad Warkentin1, Rufus Scrimger1, Naresh Jha1, David Murray1,
Matthew Parliament1 1Cross Cancer Institute, Edmonton, AB; 2University of Alberta,
Edmonton, AB
9:35–9:45
2
N OVEL ROLE OF 06-METHYLGUANINE METHYLTRANSFERASE (MGMT) IN GLIOBLASTOMA
ANGIOGENESIS AND INVASION: BIOLOGICAL AND CLINICAL SIGNIFICANCE Bassam
Abdulkarim1, Manik Chahal2, Yaoxian Xu1, Marie-Christine Guiot1, Jaw Easaw3,
Siham Sabri1 1McGill University, Montreal, QC; 2University of Alberta, Edmonton, AB;
University of Calgary, Calgary, AB
3
9:45–9:55
3
DOES DOXYCYCLINE TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
INHIBITOR RASH ALSO HAVE AN ANTI-TUMOUR EFFECT? PRELIMINARY EVIDENCE FROM CELL
CULTURE STUDIES David Palma, Peter Ferguson, Rene Figueredo, Anthony Nicolas,
Eric Winquist, Scott Ernst, James Koropatrick; London Regional Cancer Program,
London, ON
9:55–10:10
4
IRRADIATION OF THE BRAIN OF FISHER RAT PROMOTES MIGRATION OF GLIOMA CELL F98 AND
DECREASES THE LIFE EXPECTANCY OF ANIMALS Benoit Paquette, Guillaume Desmarais,
David Fortin, David Mathieu; Université de Sherbrooke, Sherbrooke, QC
10:10–10:25 Break
WEDNESDAY September 12 CARO 2012 PRECONFERENCE
2
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, OTTAWA, ON
10:25–10:40 Lung and Breast Cancer
KEY QUESTIONS AND ILLUSTRATIVE CASES
Moderators: Theodoros Tsakiridis, Bassam Abdulkarim
10:40–11:20 ABSTRACTS – LUNG AND BREAST
10:40–10:50
5
TIME AND SEQUENCE DEPENDENCY OF SORAFENIB IN COMBINATION WITH IONIZING RADIATION
IN METASTATIC BREAST CANCER MODEL Mitra Heravi, Thierry Muanza, Danuta
Radzioch; McGill University, Montreal, QC, Canada
10:50–11:00 6
ULTRASOUND AND MICROBUBBLES MEDIATED ENHANCEMENT OF GOLD NANOPARTICLES WITH
RADIOTHERAPY IN BREAST CANCER: IN VITRO STUDY Amanda Thu Lee Tran1, Gregory J
Czarnota2, Jean-Philippe Pignol2, Raffi Karshafian1 1Ryerson University, Toronto, ON;
Sunnybrook Health Sciences Centre, Toronto, ON
2
11:00–11:10 7
SESTRIN2 SENSITIZES BREAST AND LUNG CANCER CELLS TO IONIZING RADIATION THROUGH
MODULATION OF AMP-ACTIVATED PROTEIN KINASE (AMPK) Toran Sanli, Katja Linher-
Melville, Yaryna Storozhuk, Gurmit Singh, Theodoros Tsakiridis; McMaster University,
Hamilton, ON
11:10–11:20 8
PRE-IRRADIATION OF THE MAMMARY GLAND IN MICE INCREASES THE INVASIVENESS OF
BREAST CANCER CELLS AND LUNG METASTASES Benoit Paquette, Gina Bouchard,
Caroline Saucier; Université de Sherbrooke, Sherbrooke, QC
11:20–11:35 Genomic Approaches
Moderator: Robert Bristow
to Biomarkers
11:35–12:05
ABSTRACTS – BIOMARKERS
11:35–11:45
9
DICENTRIC CHROMOSOME ASSAY: A POTENTIAL BIOMARKER FOR RADIOSENSITIVITY Sara
Samiee1, Lindsay Beaton2, Scott Grimes1, Christina Addison1, Libni Eapen1, Choan
E1, Kyle Malone3, Ruth Wilkins1, Shawn Malone1 1University of Ottawa, Ottawa, ON;
Health Canada, Ottawa, ON; 3The Ottawa Hospital, Ottawa, ON
2
11:45–11:55
11:55–12:05
10
THE EFFECTS OF FRACTIONATED RADIOTHERAPY ON LYMPHOCYTE RADIATION RESPONSE Kara
Schnarr, Ian Dayes, Douglas Boreham; McMaster University, Hamilton, ON
11
CAN FDG PET DURING THE COURSE OF RADIATION THERAPY FOR LUNG CANCER PREDICT
FOR ESOPHAGITIS AND PNEUMONITIS Paula McCloskey, Victoria Ford, Nathan Becker,
Jean-Pierre Bissonnette, Katy Clarke, Jane Higgins, Claudia Leavens, Andrew
Hope, Andrea Bezjak, Alexander Sun; Princess Margaret Cancer Centre, Toronto, ON
12:05–1:00 Lunch
1:00–2:00
Keynote Room 205
DRUG-RADIOTHERAPY INTERACTIONS TO IMPROVE CURE:
PRESENT AND FUTURE Kevin Camphausen
2:00–2:15Gynecologic, Genitourinary and
KEY QUESTIONS AND ILLUSTRATIVE CASES
Moderators: Stanley Liu, Te Vuong
2:15–2:45
Gastrointestinal Tumours
ABSTRACTS – GYNE, GI AND GU
2:15–2:25 12ULTRASOUND-MICROBUBBLES COMBINED WITH CHEMOTHERAPY ENHANCED RESPONSE OF
ACURA
IONIZING RADIATION IN PROSTATE CANCER CELLS Firas Almasri1, Gregory J Czarnota2,
Shun Wong2, Raffi Karshafian1 1Ryerson University, Toronto, ON; 2Sunnybrook Health
Sciences Centre, Toronto, ON
2:25–2:35 13
DNA PLOIDY BASED ON ARCHIVED BIOPSY MATERIAL MAY CORRELATE WITH PSA RECURRENCE
AFTER PROSTATE BRACHYTHERAPY Mira Keyes1, Calum MacAulay2, Malcolm Hayes
Hayes3, Jagoda Korbelik2, Dave Garner2, W James Morris1, Branko Palcic2 1British
Columbia Cancer Agency, Vancouver, BC; 2British Columbia Cancer Research Centre,
Vancouver, BC, 3University of British Columbia, Vancouver, BC
WEDNESDAY September 12 CARO 2012 PRECONFERENCE
3
CARO • ACRO ANNUAL SCIENTIFIC MEETING
2:35–2:45
14
SEPTEMBER 12 – 15, OTTAWA, ON
T ARGETED TREATMENT WITH ANTI-EGFR ANTIBODIES AND RADIATION THERAPY FOR PATIENTS
WITH SQUAMOUS CELL CARCINOMA OF THE ANAL CANAL: RATIONALE OF STUDY PROPOSAL Té
Vuong1, Tamim Niazi1, Aleksandra Paliga2, Francois Coutlee3, Ronald Onerheim4,
George Chong5, Alex Ferenczy1, Adrian Gologan1, Marc Steben6, Alexandra De
Pokomandy7, Bernard Trottier3, Gerald Batist1 1Jewish General Hospital, Montréal, QC;
University of Ottawa, Ottawa, ON; 3CHUM, Montreal, QC; 4Saint-Mary’s Hospital, Montreal,
QC; 5McGill University, Montreal, QC; 6La Clinique A, Montreal, QC, 7Institut Thoracique de
Montreal, Montreal, QC
2
2:45–3:15
Break
3:15–5:00
ovel Biomarkers and Radiomodifiers: from Concept to Clinical
N
Trial Design Workshop
Facilitators: Bassam Abdulkarim, Theodoros Tsakiridis
OBJECTIVES:
❚ Introduce mechanisms of action of new-targeted therapies.
❚ Explore opportunities and challenges in forming a consortium of early phase
❚ Discuss preclinical evidence: in vitro and in vivo studies.
❚ Discuss design of clinical trials with biomarker selection: ongoing studies and plans.
❚ Explore interests and strengths for radio-modifier and biomarkers studies in
Canadian radiotherapy centers.
radiotherapy studies.
3:15–3:40
MOLECULAR IMAGING PROBES AS BIOMARKERS FOR CANCER TREATMENT Travis Besanger,
Anne Goodbody
3:40–3:55
TARGETING ANGIOGENESIS/INVASION IN HIGH GRADE GLIOMA: DESIGN CONSIDERATIONS FOR TRIALS
BASED ON MGMT STATUS Bassam Abdulkarim
3:55–4:10
EARLY PHASE STUDIES OF ANTI-EGFR AGENTS IN LUNG CANCER Anthony Brade
4:10–4:25
INVESTIGATIONAL BIOMARKERS FOR TUMOUR VASCULAR RESPONSE TO THERAPY Stanley Liu
4:25–4:40COMBINATION OF METFORMIN WITH CHEST RADIOTHERAPY IN LOCALLY ADVANCED NSCLC
Theodoros Tsakiridis
4:40–5:00 OPEN DISCUSSION
PROPOSAL FOR A CANADIAN PHASE I/II CONSORTIUM, FOR RADIOTHERAPY RADIO-SENSITIZER AND
BIOMARKER STUDIES OPPORTUNITIES AND CHALLENGES
5:00–5:15
Closing Remarks and Evaluation Robert Bristow
WEDNESDAY September 12 CARO 2012 PRECONFERENCE
4
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
Thursday September 13, 2012
7:00–8:00
Breakfast and Registration Level 2, Gatineau Salon
8:00–8:20 CARO Presidential
Andrea Bezjak
8:20–9:20
Address Introduction: Laval Grimard
CARO Lecture Introduction:
Changing Demographics of
Head and Neck Carcinoma Kian Ang
Guila Delouya
9:20–11:00
Resident Competition
Moderator: Kian Ang
OBJECTIVES: To review Canadian Radiation Oncology Resident Research Projects.
9:20–9:30
15
PROSPECTIVE SWALLOWING OUTCOMES AFTER INTENSITY MODULATED RADIOTHERAPY FOR
OROPHARYNGEAL CANCER: DOSIMETRIC CORRELATIONS IN A POPULATION BASED COHORT
Gordon Guo, Candace Myers, Keith Sutherland, Pascal Lambert, Jim Butler,
Ahmet Leylek, Harvey Quon University of Manitoba, Winnipeg, MB
9:30–9:40
16SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) ASSOCIATED WITH LATE RADIATION RECTAL
TOXICITY AFTER PROSTATE BRACHYTHERAPY Nelson Leong, Matthew Parliament, Kevin
Martell, Sunita Ghosh, Nadeem Pervez, John Pedersen, Don Yee, Albert Murtha,
John Amanie University of Alberta, Edmonton, AB
9:40–9:50
17RADIOGRAPHIC CHANGES AFTER LUNG STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) – CAN
WE DISTINGUISH RECURRENCE FROM FIBROSIS? A SYSTEMATIC REVIEW OF THE LITERATURE
Kitty Huang1, Max Dahele2, Suresh Senan2, Matthias Guckenberger3, George
Rodrigues1, Aaron Ward4, Gabriel Boldt4, David Palma1 1London Health Sciences
Centre, London, ON; 2VU University Medical Center, Amsterdam, Netherlands;3University
Hospital of Wuerzburg, Wuerzburg, Germany; 4University of Western Ontario, London, ON
9:50–10:00
18
PELVIC BONE MARROW DOSIMETRIC PARAMETERS AND ASSOCIATED HEMATOLOGIC
TOXICITY IN ANAL CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIATION: A
COMPARISON OF 3D-CONFORMAL AND INTENSITY MODULATED RADIOTHERAPY TECHNIQUES
Fleure Gallant1, Slobodan Devic1, Tamin Niazi1, Kamran Kafi2, Aurelie Garant1,
Isabelle Lavoie1, Christina Holcroft1, Te Vuong1 1Jewish General Hospital, Montreal, QC;
McGill University, Montreal, QC
2
10:00–10:10
19
MULTIDISCIPLINARY ASSESSMENT AND REPORTING OF FITNESS TO DRIVE IN BRAIN TUMOUR
PATIENTS: A GRAY MATTER Alexander Louie1, Esther Chan2, Michelle Hanna1, David
Palma1, Glenn Bauman1, Barbara Fisher1, George Rodrigues1, Abhinay Sathya1,
David D’Souza1 1London Regional Cancer Program, London, ON; 2University of Western
Ontario, London, ON
10:10–10:20
20UTILIZATION OF PREOPERATIVE RADIOTHERAPY FOR RECTAL CANCER PATIENTS IN MANITOBA:
A POPULATION-BASED ANALYSIS Benjamin Mou, Andrew L Cooke, Lin Xue CancerCare
Manitoba, Winnipeg, MB
10:10–10:20
21
USE OF PROTOPORPHYRIN FLUORESCENCE TO DETERMINE CLINICAL TARGET VOLUME
MARGINS FOR NON-MELANOTIC SKIN CANCERS TREATED WITH PRIMARY RADIOTHERAPY
Lara Best1, Olga Vujovic2, Kevin Jordan2, Barbara Fisher2, Deb Carey1, Deborah
Bourdeau1, Edward Yu2 1London Regional Cancer Program, London, ON; 2University of
Western Ontario, London, ON
10:30–10:40
22IMPROVING TARGET COVERAGE FOR POST-OPERATIVE PROSTATE CANCER PATIENTS Jennifer
Croke1, Balazs Nyiri2, Yan Li2, Len Avruch2, Eric Belanger2, Chris Morash2,
Cathleen Kayser2, Kyle Malone2, Shawn Malone2 1University of Ottawa, Ottawa, ON;
2
The Ottawa Hospital, Ottawa, ON
THURSDAY September 13 CARO 2012
5
CARO • ACRO ANNUAL SCIENTIFIC MEETING
10:40–10:50
SEPTEMBER 12 – 15, Ottawa, ON
23PREDICTORS OF PROSTATE BED CONTOURING VARIABILITY: AN INTERNATIONAL CONTOURING
CASARIACHALLENGE Vikram Velker1, Alexander Louie1, Jay Markham2, George Rodrigues1
London Regional Cancer Program, London, ON; 2Radiation Oncology Resources, Goshen, IN
1
10:50–11:00
24MORE RADIATION ONCOLOGISTS TRANSLATES TO MORE CANCER PATIENTS RECEIVING MORE
TIMELY TREATMENT Inge Aivas1, Vusal Babashov1, Mehmet Begen1, Greg Zaric1,
Jeffrey Cao2, Derrick Fournier1, David D’Souza1, George Rodrigues1, Michael Lock1
University of Western Ontario, London, ON; 2University of British Columbia, Vancouver, BC
1
11:00–11:30 Break
11:30–12:40 Theme
Symposium
Moderator: Robert Bristow
DEBATE with post-Debate Panel and Open Discussion
Keynote Debaters: Kian Ang, Kevin Camphausen
This house believes molecular targeted drugs and radiation therapy will supplant
12:30–2:30
2:30–3:30
standard chemotherapy and radiation therapy in head and neck cancer.
Lunch – on your own
Poster Preview 1 ABSTRACTS 25–74
Moderators: Christina Parsons, Tara Rosewell
25DOES THE STAGING OF CERVICAL CANCER
PATIENTS, TREATED WITH CHEMORADIATION,
BY LYMPHADENECTOMY, PET, OR MRI HAVE
A SURVIVAL IMPACT? Joanne Alfieri1,
London, ON
IN PATIENTS WITH VULVAR SQUAMOUS CELL
CARCINOMA TREATED WITH RADIOTHERAPY
LYMPH NODES IN MANAGEMENT OF CERVIX
CARCINOMA WITH CONCURRENT CHEMORADIOTHERAPY Julie Cuartero, Mei Ling
Margaret Cancer Centre, Toronto, ON
28 TREATMENT OUTCOMES OF STAGE IIIC
ENDOMETRIAL CANCER TREATED WITH PELVIC
OR EXTENDED FIELD IRRADIATION Caroline
Holloway1, Cheryl Alexander1, Caroline
Walter1, Christina Aquino-Parsons2,
Pauline Truong1 1British Columbia Cancer
Agency, Vancouver Island Centre, Victoria, BC;
2
British Columbia Cancer Agency, Vancouver
Centre, Vancouver, BC
THURSDAY September 13 CARO 2012
31ACCUMULATED VERSUS PLANNED DOSIMETRY IN
PULSED DOSE RATE (PDR) BRACHYTHERAPY FOR
CERVICAL CARCINOMA BASED ON SOFT TISSUE
DEFORMATION ANALYSIS Mei Ling Yap, Julie
Cuartero, Seungjong Oh, Young-bin Cho,
Marita Morgia, Xie Jason, Levin Wilfred,
Lee Manchul, Anthony Fyles, Michael
Milosevic Princess Margaret Cancer Centre,
27ELECTIVE RADIOTHERAPY TO PARA-AORTIC
Yap, Jing Yan, Melania Pintilie, Krisha
Opfermann, Wilfred Levin, Lee Manchul,
Michael Milosevic, Anthony Fyles Princess
OPERATIVE GYNECOLOGIC IMRT WITH SINGLE
CT SIMULATION: DOSIMETRIC ADVANTAGES
COMPARED TO 3D-CONFORMAL Ericka Wiebe,
Toronto, ON
Princess Margaret Cancer Centre, Toronto, ON
30CLINICAL IMPLEMENTATION OF POST-
Joe Presutti, Melanie Davidson, Kitty
Yip, Ida Ackerman, Toni Barnes, Gillian
Thomas, Lisa Barbera Odette Cancer Centre,
26HUMAN PAPILLOMA VIRUS, P16 AND P53 STATUS
Julie Cuartero, Ghassan Allo, Mei Ling
Yap, Melania Pintilie, Anthony Fyles, Joan
Murphy, Helen Mackay, Suzanne KamelReid, Michael Milosevic, Blaise Clarke
CASES UNSUITABLE FOR GYNECOLOGICAL
BRACHYTHERAPY Nikhilesh Patil, George
Hajdok, Brian Yaremko, Kathleen Surry,
Michel Prefontaine, Akira Sugimoto,
David D’Souza University of Western Ontario,
Thomas Jobling2, Kailash Narayan3,
David Bernshaw3, Srinivas KondalsamyChennakesavan4 1McGill University Health
Centre, Montreal, QC; 2Monash University,
Melbourne, Victoria, Australia; 3University of
Melbourne, Melbourne, Victoria, Australia;
4
Royal Brisbane and Women’s Hospital, Herston,
Queensland, Australia
29 STEREOTACTIC BODY RADIOTHERAPY IN
Toronto, ON
32DOSE CONFORMALITY AND ACUTE TOXICITY
ANALYSIS IN PATIENTS WITH PROSTATE
ADENOCARCINOMA TREATED WITH VOLUMETRIC
MODULATED ARC THERAPY (VMAT) VERSUS
CONVENTIONAL INTENSITY MODULATED
RADIATION THERAPY (IMRT) David Cuthbert,
Charles Catton, Patricia Lindsay, Haiyan
Jiang, Robert Bristow, Elantholi P
Saibishkumar, Cynthia Ménard, Lucy Lu,
Andrew Bayley Princess Margaret Cancer
Centre, University of Toronto, Toronto, ON
6
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
33ACUTE TOXICITY IN HIGH-RISK PROSTATE CANCER 40A RANDOMIZED TRIAL COMPARING SEED LOSS
PATIENTS TREATED WITH HYPOFRACTIONATED
IMRT WITH SIMULTANEOUS INTEGRATED BOOST
AND DISPLACEMENT OF ANCHORSEEDS TO
STANDARD UNCOATED LOOSE SEEDS David
Bowes1, Juanita Crook2, Deidre Batchelar2,
Cynthia Araujo2, Brent Parker2, David
Kim2, Miren Gaztanaga2, Marie-Pierre
Milette2, Rasika Rajapakshe2, David
Petrik2, Ross Halperin2 1Nova Scotia Cancer
Magali Lecavalier-Barsoum, Sergio Faria,
Russel Ruo, Fabio Cury, Marc David, Marie
Duclos, Luis Souhami McGill University
Health Centre, Montreal, QC
34HYPOFRACTIONATED AND CONVENTIONALLY
FRACTIONATED RADIOTHERAPY SCHEDULES
FOR LOCALIZED PROSTATE CANCER Gary
Mok1, Jarad Martin2, Christine Massey1,
Andrew Bayley1, Cynthia Ménard1, Peter
Chung1, Robert Bristow1, Padraig Warde1,
Mary Gospodarowicz1, Charles Catton1
Princess Margaret Cancer Centre, Toronto, ON;
2
Radiation Oncology Queensland, Toowoomba,
Queensland, Australia
Agency, Halifax, NS; 2British Columbia Cancer
Agency, Kelowna, BC
35RADIOTHERAPY AFTER RADICAL PROSTATECTOMY:
Ottawa, ON
TREATMENT RECOMMENDATIONS DIFFER
BETWEEN UROLOGISTS AND RADIATION
ONCOLOGISTS Luke Lavallee1, Scott Morgan1,
Dean Fergusson2, Renee Grenon1, Franco
Momoli2, Christopher Morash1, Ilias
Cagiannos1, Rodney Breau1 1University of
Ottawa Regional Cancer Centre, Ottawa, ON;
University of Ottawa, Ottawa, ON
36USE OF PRE-OP MRI AND ‘3D PROSTATE CANCER
45RETROSPECTIVE REVIEW OF PATHOLOGY
46DOWNSIZING AND DOWNSTAGING OF LOCALLY
Cancer Agency, Vancouver, BC; University of
Western Ontario, Kitchener, ON; 3McMaster
University, Hamilton, ON
38PSA BOUNCE AFTER HDR PROSTATE
BRACHYTHERAPY AND HYPOFRACTIONATED
EXTERNAL BEAM RADIOTHERAPY Nita Patel,
Fabio Cury, Luis Souhami, Armen Aprikian,
Sergio Faria, Marc David, Marie Duclos
McGill University Health Centre, Montreal, QC
39THE IMPACT OF COMORBIDITIES ON THE
BENEFITS OF PROLONGED ANDROGEN ABLATION
IN PATIENTS WITH T3-4 PROSTATE CANCER
FOR STAGE II TESTICULAR SEMINOMA – MAYO
CLINIC EXPERIENCE Chunhee Richard
Rochester, MN
2
44LONG-TERM OUTCOMES OF RADIOTHERAPY
Choo, Christopher Hallemeier Mayo Clinic,
37LATE RESULTS OF PURE HYPOFRACTIONATION
Darin Gopaul2, Omar Qazi3, Pierre Fortin2,
Ramana Rachakonda3 1British Columbia
WITH PLATINUM SEED INTERNAL FIDUCIAL
MARKERS FOR CT-MRI FUSION AND REAL-TIME
TUMOUR TRACKING DURING STEREOTACTIC
ABLATIVE RADIOTHERAPY Vimoj Janardanan
of Ottawa, Ottawa, ON
The Ottawa Hospital, Ottawa, ON; 2University of
Ottawa, Ottawa, ON
FOR PROSTATE CANCER Dilip Panjwani1,
43FEASIBILITY, DETECTABILITY AND EXPERIENCE
Nair, Janos Szanto, Eric Vandervoort,
Elizabeth Henderson, Leonard Avruch,
Shawn Malone, Jason Pantarotto University
MAPS’ TO IMPROVE CTV DEFINITION FOR
POST-OPERATIVE PROSTATE RADIATION Shawn
1
FOLLOWING POSTPROSTATECTOMY
RADIOTHERAPY Libni Eapen1, Ionut Busca2
2
Ottawa, Ottawa, ON; Ottawa Hospital Research
Institute, Ottawa, ON
Malone1, Jennifer Croke2, Eric Belanger1,
Kyle Malone1, Len Avruch1, Colin Malone2,
Chris Morash1, Yan Li1, Balazs Nyiri1
42SPHINCTER CONDITIONING EXERCISES
1
2
ON PROSTATE POSITION AND DOSE DISTRIBUTION
DURING PERMANENT SEED IMPLANTATION
Amanda Cherpak, Joanna Cygler, Choan E,
Gad Perry The Ottawa Hospital Cancer Centre,
1
41IMPACT OF TRANSRECTAL ULTRASOUND PROBE
REPORTS OF PATIENTS DIAGNOSED WITH
PENILE CANCER OVER A PERIOD OF 10 YEARS
IN ONTARIO Darwin Yip, Aamer Mahmud
Queen’s University, Kingston, ON
ADVANCED RECTAL CANCER AFTER SHORT
COURSE RADIOTHERAPY (RT) FOLLOWED
BY DELAYED SURGERY Sergio Faria1, Neil
Kopek1, Tarek Hijal1, Sender Liberman1,
Patrick Charlebois1, Barry Stein1, Sarkis
Meterissian1, Ari Meguerditchian1, Eric
Debroux2, Donna Tataryn3 1McGill University,
Montreal, QC; 2University of Montreal, Montreal,
QC; 3St Mary’s Hospital, Montreal, QC
Eric Tran, Matthew Paquette, Justin Jay,
Mitchell Liu, Jeremy Hamm, Graeme
Duncan, Tom Pickles, Scott Tyldesley
British Columbia Cancer Agency, Vancouver, BC
THURSDAY September 13 CARO 2012
7
CARO • ACRO ANNUAL SCIENTIFIC MEETING
47CLINICAL TARGET VOLUME DELINEATION OF
LIVER TUMOURS ON 4D-CT, DYNAMIC CONTRAST
ENHANCED CT AND PERFUSION CT Nikolaj
SEPTEMBER 12 – 15, Ottawa, ON
Jensen1, Danielle Mulder2, Michael Lock2,
Barbara Fisher2, Roman Kozak3, Ting-Yim
Lee4, Jeff Chen2, Eugene Wong1 1University
48COMPARISON OF ADJUVANT CHEMORADIATION
(MCDONALD) AND PERI-OPERATIVE
CHEMOTHEARPY (MAGIC) FOR THE TREATMENT
OF GASTRIC AND GASTROESOPHAGEAL JUNCTION
ADENOCARCINOMA Haerin Kim1, Devin
Toronto, Toronto, ON
49ONE VERSUS TWO CYCLES OF MITOMYCIN C IN
CONCURRENT CHEMORADIATION FOR TREATMENT
OF ANAL CANAL CARCINOMA: AN ANALYSIS OF
OUTCOMES AND TOXICITY
University of Calgary, Calgary, AB; 2University of
Alberta, Edmonton, AB
1
50A PROSPECTIVE STUDY TO UNDERSTAND THE
EARLY HEMATOLOGICAL EFFECTS OF CHEMORADIATION THERAPY IN CANCER PATIENTS
AND THEIR PATTERN OF RECOVERY Manpreet
Breitman, Hudson Alana, Rao Khan,
Harold Lau, Lesiuk Mark, Gerald Lim,
Chris Newcomb, Robert Nordal, David
Spencer Tom Baker Cancer Centre, Calgary, AB
57 INCIDENCE OF PAIN FLARE FOLLOWING
STEREOTACTIC BODY RADIOTHERAPY FOR BONE
METASTASES Andrew Chiang, Liang Zeng,
Kaitlin Koo, Edward Chow, Fiona Lochray,
Laura Masucci, Renee Korol, Arjun Sahgal
58IMPROVING ACCESS TO SPECIALIZED
TECHNIQUES IN CANCER TREATMENT – AN
EXAMPLE OF STEREOTACTIC RADIOSURGERY FOR
BRAIN METASTASES Fred Hsu1, Alan Nichol2,
Agency, Abbotsford, BC; 2British Columbia
Cancer Agency, Vancouver, BC
51EVALUATION OF LOCAL CONTROL AND RADIATION 59MONTE CARLO CALCULATION OF DOSE
DOSE RESPONSE FOR RADIATION THERAPY
DISTRIBUTION IN OLIGOMETASTATIC PATIENTS
PLANNED FOR SPINE STEREOTACTIC ABLATIVE
RADIOTHERAPY Shaun Loewen, Vitali
OF PRIMARY AND METASTATIC LIVER CANCER
Anthony Lausch, Kevin Sinclair, Michael
Lock, Barbara Fisher, Nikolaj Jensen,
Stewart Gaede, Jeff Chen, Eugene Wong
Moiseenko, I Anthony Popescu, Rose
Vellani, Ming Fong, Mitchell Liu British
University of Western Ontario, London, ON
52 OUTCOME OF STEREOTACTIC BODY RADIATION
THERAPY FOR PRIMARY HEPATOCELLULAR
CARCINOMA PATIENTS: RESULTS FROM TWO
INSTITUTIONS Melissa Azoulay1, Neil Kopek2,
David Roberge3 1McGill University, Montreal,
QC; 2McGIll University Health Centre, Montreal,
QC; 3Centre Hospitalier de l’Université de
Montréal, Montreal, QC
FOR FRAME-LESS RADIOSURGERY FOR BRAIN
METASTASES Jon-Paul Voroney, Karen
Richard Lee1, Roy Ma1, Arthur Cheung2,
Michael McKenzie1 1British Columbia Cancer
and Hospital, Ludhiana, India
56INVESTIGATING POTENTIAL UTILITY OF A MOCK
University of Toronto, Toronto, ON
Tiwana, Hsueh Ni Lee, Manmohan
Mahajan, Sheila Das, Pamela Jeyaraj,
Jaineet Sachdeva Christian Medical College
UPTAKE AND UTILIZATION OF STEREOTACTIC
RADIOSURGERY (SRS) FOR BRAIN METASTASIS IN
NOVA SCOTIA Gaurav Bahl, Karl Tennessen,
Dalhousie University, Halifax, NS
Rosanna Yeung1, Yarrow McConnell1,
George Roxin1, Robyn Banerjee1, Gloria B
Roldán Urgoiti1, Anthony R MacLean1, W
1
2
Donald Buie , Karen E Mulder , Michael M
Vickers1, Kurian J Joseph2, Corinne M Doll1
55A POPULATION-BASED STUDY ON THE
Ashraf Mahmoud-Ahmed, Dorianne
Rheaume, Ian Fleetwood, Liam Mulroy
Schellenberg2, Christian Kollmannsberger1,
Winson Cheung1, Howard Lim1 1British
Columbia Cancer Agency, Vancouver, BC;
2
British Columbia Cancer Agency, Surrey, BC
HYPOFRACTIONATED STEREOTACTIC CAVITY
RADIOTHERAPY (HSCRT) AS SALVAGE FOR
PATIENTS WITH PRIOR WHOLE BRAIN RADIATION
(WBRT) AS COMPARED TO UPFRONT ADJUVANT
HSCRT Ameen Alomair, Hany Soliman,
Wei Xu, Aliaksandr Karotki, Nicolas Phan,
Sunit Das, James Perry, May Tsao, Todd
Mainprize, Arjun Sahgal University of
of Western Ontario, London, ON; 2London
Regional Cancer Program, London, ON; 3St.
Josephs Health Care, London, ON; 4Robarts
Research Institute, London, ON
54 OUTCOMES FOR POST-SURGICAL
53LATE SIDE EFFECTS OF PRE-OPERATIVE
ENDORECTAL BRACHYTHERAPY AND TOTAL
MESORECTAL EXCISION IN RECTAL CANCER
PATIENTS Daniel Bernad1, Hani Al-Halabi1,
Tamim Niazi , Christina Holcroft , Diana
Mohid1, Té Vuong2 1McGill University,
2
1
Montreal, QC; 2Jewish General Hospital,
Montreal, QC
THURSDAY September 13 CARO 2012
Columbia Cancer Agency, Vancouver, BC
60INTEGRATION OF DIFFUSION TENSOR
TRACTOGRAPHY IN PATIENTS WITH
ARTERIOVENOUS MALFORMATION TREATED
WITH STEREOTACTIC RADIOSURGERY Shaun
Loewen1, Michael McKenzie1, Ermias
Gete1, Bradford Gill1, Richard Lee1,
Kurt Luchka1, Vitali Mioseenko1, Chris
Herbert1, Brian Toyota2, Gary Redekop2,
Charles Haw2, Andy Lee3, Monty Martin1,
Yervant Arzoumanian1 1British Columbia
Cancer Agency, Vancouver Cancer Centre,
Vancouver, BC; 2Vancouver General Hospital,
Vancouver, BC; 3Royal Columbian Hospital, New
Westminster, BC
8
CARO • ACRO ANNUAL SCIENTIFIC MEETING
61 DEVELOPING THE NCIC-CTG SC 24 RANDOMIZED
PHASE II SPINE SBRT (STEREOTACTIC BODY
RADIATION THERAPY) STUDY FOR COMPLEX
SPINAL METASTASES: WHAT SHOULD THE
CONTROL GROUP BE? Giuseppina Laura
Masucci1, Rebecca Wong2, Michael
Brundage3, Heather Stanton3, Carolyn
Wilson3, Ralph Meyer3, Arjun Sahgal2
SEPTEMBER 12 – 15, Ottawa, ON
Ottawa, ON; 2University of Ottawa, Ottawa, ON
Université de Montréal, Montréal, QC; 2University
of Toronto, Toronto, ON; 3Queen’s University,
Kingston, ON
62PROBABILITIES OF RADIATION MYELOPATHY
SPECIFIC TO STEREOTACTIC BODY
RADIOTHERAPY TO GUIDE SAFE PRACTICE
Arjun Sahgal , Vivian Weinberg , Lijun
Ma2, Eric Chang3, Sam Chao4, Alexander
Muacevic5, Alessandra Gorgulho6, Iris
Gibbs7, Scott Soltys7, Peter Gerszten8,
Liliyanna Angelov4, Shun Wong1, David
Larson2 1University of Toronto, Toronto, ON;
1
London Regional Cancer Program, London, ON;
University of Western Ontario, London, ON
2
British Columbia Cancer Agency, Vancouver, BC;
University of British Columbia, Vancouver, BC
2
University of British Columbia, Vancouver, BC;
British Columbia Cancer Agency, Vancouver, BC
2
Toronto, ON
COMPONENT OF COMPREHENSIVE RADIATION
ONCOLOGIC CARE – A PEI PROVINCIAL STUDY
Treatment Centre, Charlottetown, PE
73OPERATING CHARACTERISTICS RELATED TO
BRAIN METASTASES PROGNOSTIC INDICES
George Rodrigues1, Glenn Bauman1,
David Palma1, Alexander Louie1,
Joseph Mocanu1, Suresh Senan2, Frank
Lagerwaard2 1University of Western Ontario,
TERM PEDIATRIC BRAIN TUMOUR SURVIVORS:
PARENTS’ PERSPECTIVES Karen Goddard,
Lalani, Ashraf Almatar, Suzanne Richter,
Jackie Bender, David Wiljer, Laura Legere,
Christine Massey, Srikala Sridhar, Michael
Jewett, Pamela Catton University of Toronto,
72ENSURING HIGH QUALITY OF LIFE AS A
Larry Pan, Gwen MacDonald, Judy Hale,
Liz Dobbin, Ethan Laukkanen PEI Cancer
65LIFE CHALLENGES EXPERIENCED BY LONG-
GENITOURINARY ONCOLOGY: TOWARDS A
MULTIDISCIPLINARY PERSPECTIVE Nafisha
ACTIVITIES, AND COGNITIVE FUNCTION, FROM
BASELINE TO 6 MONTHS POST-TREATMENT, FOR
PATIENTS WITH HIGH GRADE GLIOMAS Robert
1
REVIEW OF STEREOTACTIC BODY RADIOTHERAPY (SBRT) TREATMENT PLANNING FOR LUNG CANCER
66SURVIVORSHIP CARE IN CANADIAN
71CHANGES IN QUALITY OF LIFE, FUNCTIONAL
Olson1, Maureen Parkinson1, Rosemary
Cashman2, Michael McKenzie1, Jennifer
Yao1, Gina Mackenzie2, Joanne Stephen1
64 A PROVINCE-WIDE QUALITY ASSURANCE (QA)
Vancouver, BC
DEPRESSION LEVELS AT TIME OF DIAGNOSIS
IN STAGE III LUNG CANCER PATIENTS Sarah
Lucas1, Wolfgang Linden2, Robert Olson2
SPINE STEREOTACTIC BODY RADIOTHERAPY
(SBRT): DOES THE CORD MOVE? Chia-Lin
Robert Olson, Maureen Parkinson, Wendy
Nurcombe, Mary Anne Bobinski, Fuchsia
Howard British Columbia Cancer Agency,
70PROGNOSTIC UTILITY OF ANXIETY AND
1
Andrea Lo1, Mitchell Liu1, Elisa Chan1,
Chad Lund2, Shaun Loewen1, Jeffrey Cao1,
Devin Schellenberg2, Hannah Carolan1,
Tanya Berrang3 1University of British
MALIGNANT AIRWAY OBSTRUCTION: FUTILE, OR
FACILITATING EXTUBATION? Alexander Louie1,
1
63 SPINAL CORD MOTION CONSIDERATIONS FOR
Columbia, Vancouver, BC; 2University of British
Columbia, Surrey, BC; 3University of British
Columbia, Victoria, BC
69RADIOTHERAPY FOR INTUBATED PATIENTS WITH
Sophia Lane2, David Palma1, Jeffrey Cao1,
Andrew Warner1, George Rodrigues1
Tseng, Marshall Sussman, Anna Simeonov,
Daniel Letourneau, Eugene Yu, Arjun
Sahgal University of Toronto, Toronto, ON
FUNCTION IN HOMOSEXUAL MEN TREATED FOR
PROSTATE CANCER Tsz Kin Lee1, Rodney
Hospital Cancer Centre, Ottawa, ON; 2University
of Ottawa, Ottawa, ON
2
68PILOT STUDY ON QUALITY OF LIFE AND SEXUAL
Henry Breau2, Libni Eapen2 1The Ottawa
2
University of California San Francisco, San
Francisco, CA; 3MD Anderson Cancer Center,
Houston, TX; 4Cleveland Clinic, Cleveland,
OH; 5University Hospitals of Munich, Munich,
Germany; 6University of California Los Angeles,
Los Angeles, CA; 7Stanford, Palo Alto, CA;
8
University of Pittsburgh, Pittsburgh, PA
DATA AFTER PROSTATE CANCER TREATMENT
Tsz Kin Lee1, Rodney Henry Breau2, Libni
Eapen2 1The Ottawa Hospital Cancer Centre,
1
67 SYSTEMATIC REVIEW OF EPIC QUALITY OF LIFE
London, ON; 2VU Amsterdam, Amsterdam,
Netherlands
74CONCERNS AND PERCEPTIONS REGARDING
QUALITY AND SAFETY IN RADIATION THERAPY
AMONGST CANCER PATIENTS Caitlin Gillan1,
Kaleigh Briggs2, Teresa Cheng3, Nicole
Harnett1, David Wiljer1 1University of Toronto,
Toronto, ON; 2Princess Margaret Cancer Centre,
Toronto, ON; 3The Michener Institute for Applied
Health Sciences, Toronto, ON
3:30–3:40
Stretch your legs and get ready for
Round 2!
THURSDAY September 13 CARO 2012
9
CARO • ACRO ANNUAL SCIENTIFIC MEETING
3:40–4:40
SEPTEMBER 12 – 15, Ottawa, ON
Poster Preview 2 ABSTRACTS 75–124
Moderators: Christina Parsons, Tara Rosewell
75 TMPRSS2:ERG STATUS AND BIOCHEMICAL
RECURRENCE FOLLOWING RADIOTHERAPY
FOR INTERMEDIATE-RISK PROSTATE CANCER
Alan Dal Pra1, Fiona Warde1, Adrian
Ishkanian1, Alice Meng1, Chad Maloff2,
Wan Lam2, Jenna Sykes1, Melania
Pintile1, Jeremy Squire3, Anthony Joshua1,
Gyorgy Petrovics4, Theo van der Kwast1,
Tarek Bismar5, Andrew Evans1, Michael
Milosevic1, Robert Bristow1 1University of
Toronto, Toronto, ON; British Columbia Cancer
Research Centre, Vancouver, BC; 3Queen’s
University, Kingston, ON; 4Uniformed Services
University of the Health Sciences, Rockville,
MD; 5University of Calgary, Calgary, AB
2
76GENE PROFILE ANALYSIS UNCOVERS
MOLECULAR SUBTYPES OF CERVICAL CANCER
Corinne Doll1, Peter Craighead1, Prafull
Ghatage1, Susan Lees-Miller1, Anthony
Magliocco2 1University of Calgary, Calgary, AB;
Moffitt Cancer Center, Tampa, FL
2
77MICRORNA-193B ENHANCES TUMOUR
PROGRESSION VIA DOWN REGULATION OF
NEUROFIBROMIN 1 Michelle Lenarduzzi1,
Angela Hui2, Nehad Alajez3, Wei Shi2,
Justin Williams2, Shijun Yue2, Fei-Fei Liu2
University of Toronto, Toronto, ON; 2Princess
Margaret Cancer Centre, Toronto, ON; 3King
Saud University, Riyadh, Saudi Arabia
1
78HUMAN PAPILLOMA VIRUS INFECTION AND
ERYTHROPOIETIN RECEPTOR EXPRESSION AS
PROGNOSTIC INDICATORS IN OROPHARYNGEAL
CANCER Lily Shakibnia1, Hani Marzouki2,
Eduardo Franco2, Peter Chauvin2, James
Hanley2, François Coutlée2, Karen Kost2,
George Shenouda1 1McGill University Health
Centre, Montreal, QC; 2McGill University,
Montreal, QC
79
COMBINING GEROSUPPRESSANTS WITH
CURA
A
RADIOTHERAPY IN PROSTATE AND LUNG CANCER
MODELS Thomas Corbett Tsakiridis Juravinski
Cancer Centre, Hamilton, ON
80
A POTENTIAL PROGNOSTIC MICRO-RNA
ELEKTA
SIGNATURE FOR DISTANT METASTASIS IN SOFTTISSUE SARCOMAS Philip Wong, Angela
Hui, Jie Su, Wei Xu, Christine How, Jeff
Bruce, Charles Catton, Jay Wunder,
Irene Andrulis, Brendan Dickson, Brian
O’Sullivan, Robert Bell, Fei-Fei Liu
University of Toronto, Toronto, ON
81 DETERMINING THE USE OF IGRT FOR
ELEKTA
PRE-OPERATIVE RADIOTHERAPY OF
RETROPERITONEAL SARCOMAS Philip Wong,
82
COST MINIMIZATION ANALYSIS: SHOULD
PARTIAL BREAST IRRADIATION BE UTILIZED
OVER WHOLE BREAST IRRADIATION? Martin
Leung1, Michael Lock1, Alexander Louie1,
George Rodrigues1, David D’Souza1,
Robert Dinniwell2, Rob Barnett1 1University
of Western Ontario, London, ON; 2University of
Toronto, Toronto, ON
83
SHOULD WOMEN YOUNGER THAN 40 YEARS
ELEKTA
OF AGE WITH INVASIVE BREAST CANCER HAVE
A MASTECTOMY? 15–YEAR OUTCOMES OF A
POPULATION-BASED COHORT Jeffrey Cao, Ivo
Olivotto, Pauline Truong, Robert Olson,
Mira Keyes, Lorna Weir, Karen Gelmon,
Vanessa Bernstein, Ryan Woods, Caroline
Speers, Scott Tyldesley University of British
Columbia, Vancouver, BC
84
LONG TERM MORTALITY FROM CARDIAC CAUSES
AFTER ACCELERATED HYPOFRACTIONATED
VERSUS CONVENTIONAL WHOLE BREAST
RADIOTHERAPY FOR LOCALIZED LEFT-SIDED
BREAST CANCER Elisa K Chan, Ryan Woods,
Sean Virani, Caroline Speers, Elaine
Wai, Alan Nichol, Mary L McBride, Scott
Tyldesley University of British Columbia,
Vancouver, BC
85THE EFFECT OF A BOOST ON PATIENT REPORTED
LONG-TERM COSMETIC OUTCOME AFTER
ACCELERATED HYPOFRACTIONATED WHOLE
BREAST RADIOTHERAPY FOR LOCALIZED BREAST
CANCER Elisa K Chan, Nazlee Tabarsi,
Scott Tyldesley, Mohamed Khan, Ryan
Woods, Caroline Speers, Lorna Weir
University of British Columbia, Vancouver, BC
86IDENTIFYING RISK FACTORS FOR LOCOREGIONAL
RECURRENCE FOLLOWING POSTMASTECTOMY
RADIOTHERAPY IN BREAST CANCER PATIENTS
Lynn Chang1, Tim Whelan2, Chu-Shu Gu2,
Jim Julian2, Claire McMillan3, Sue Schiff3,
Do-Hoon Kim2 1Juravinski Cancer Centre,
Hamilton, ON; 2McMaster University, Hamilton,
ON; 3Hamilton Health Sciences, Hamilton, ON
87MULTICENTRE OUTCOMES IN WOMEN WITH
BREAST DUCTAL CARCINOMA IN SITU USING
HYPOFRACTIONATED RADIOTHERAPY Lara
Hathout1, Tarek Hijal2, Horia Vulpe2,
Houda Bahig3, Bernard Fortin3, Michael
Yassa3 1Université de Montréal, Montreal, QC;
MUHC Montreal General Hospital, Montreal,
QC; 3Hôpital Maisonneuve-Rosemont, Montreal,
QC
2
Colleen Dickie, David Lee, Peter Chung,
Brian O’Sullivan, Carol Swallow, Rebecca
Gladdy, Charles Catton University of Toronto,
Toronto, ON
THURSDAY September 13 CARO 2012
10
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
88TREATMENT PATTERNS AND LOCOREGIONAL
RECURRENCE OUTCOMES IN PATIENTS WITH PN0
(I+) BREAST CANCER Irene Karam1, Maria
F Lesperance2, Scott Tyldesley3, Caroline
Speers3, Mary L Lesperance2, Pauline T
Truong4 1British Columbia Cancer Agency,
Vancouver Centre, Vancouver, BC; 2University
of Victoria, Victoria, BC; 3University of British
Columbia, Vancouver, BC; 4British Columbia
Cancer Agency, Vancouver Island Centre,
Victoria, BC
Ryerson University, Toronto, ON
RECONSTRUCTION WITH AND WITHOUT
POSTMASTECTOMY RADIATION: PREDICTIVE
FACTORS FOR COMPLICATIONS Sonia Kim Anh
Gerald Lim2 1University of Calgary, Calgary, AB;
Tom Baker Cancer Centre, Calgary, AB
2
93FACTORS INFLUENCING OVERALL SURVIVAL
SPECIFIC TO ADULT LOW-GRADE ASTROCYTOMA:
A POPULATION-BASED STUDY Sarah Ironside,
James Perry, May Tsao, Todd Mainprize,
Julia Keith, Normand Laperriere, Lawrence
Paszat, Arjun Sahgal University of Toronto,
98ROLE OF DOSE ESCALATION IN THORACIC
RADIOTHERAPY FOR LIMITED-STAGE SMALL
CELL LUNG CANCER: ANALYSIS OF THE 15 YEAR
EXPERIENCE FROM A RETROSPECTIVE COHORT
OF 296 PATIENTS AT THE OTTAWA HOSPITAL
CANCER CENTRE (TOHCC) Vimoj Janardanan
Nair, Abby Sirisegaram, Garth Nicholas,
Ranjeeta Mallick, Scott Laurie, Robert
MacRae University of Ottawa, Ottawa, ON
99CHEMORADIATION WITH ACCELERATED BOOST
FOR STAGE III NONSMALL CELL LING CANCER
Ethan Laukkanen1, Larry Pan1, Philip
Champion1, Faraz Khan2, D Dryer1,
Christina Schipper1 1Queen Elizabeth Hospital
PEI, Charlottetown, PE; 2Dubai, United Arab
Emirates
92INCIDENCE AND OUTCOME OF SYMPTOMATIC
VENOUS THROMBOEMBOLISM IN PATIENTS WITH
GLIOBLASTOMA MULTIFORME IN SOUTHERN
ALBERTA Clement Ho1, Jacob Easaw1,
OF PROPHYLACTIC CRANIAL IRRADIATION ON
NEUROCOGNITIVE FUNCTION IN PATIENTS WITH
LIMITED STAGE SMALL CELL LUNG CANCER
2
91TISSUE EXPANDER/IMPLANT BREAST
Columbia Cancer Agency, Fraser Valley Centre,
Surrey, BC; 2University of British Columbia,
Surrey, BC; 3University of British Columbia,
Vancouver, BC; 4Simon Fraser University,
Surrey, BC
97 PILOT STUDY INVESTIGATING THE EFFECTS
Daniel Bernad1, Alexandra Fiocca2, George
Shenouda1, Valerie Panet-Raymond1,
Paul Giacomini1, Raquel del Carpio1, Luis
Souhami1 1McGill University, Montreal, QC;
PNEUMONITIS IN NEOADJUVANT CONCURRENT
DOCETAXEL AND RADIATION THERAPY FOR
LOCALLY ADVANCED BREAST CANCER Alexander
Nguyen1, Paul Oxley1, Rashin Rastagar2,
Michel Joffres3, Winkle Kwan4 1British
SINGLE INSTITUTION EXPERIENCE Jim Rose1,
Kerry Savage2, Christina Aquino-Parsons2
Cancer Centre of Southeastern Ontario,
Kingston, ON; 2British Columbia Cancer Agency,
Vancouver, BC
London, ON
96NATURAL KILLER/T CELL LYMPHOMA: A CANADIAN
1
90PROSPECTIVE EVALUATION OF RADIATION
Louie, George Rodrigues, Abhinay
Sathya, Francisco Perera, Michael Ong,
David D’Souza, Ann Chambers, Muriel
Brackstone London Regional Cancer Program,
LIMITED STAGE PRIMARY CUTANEOUS B-CELL
LYMPHOMA Sarah Hamilton1, Elaine Wai2,
Columbia Cancer Agency, Vancouver, BC;
2
British Columbia Cancer Agency, Victoria, BC
1
Columbia Cancer Agency, Vancouver Island,
Victoria, BC; 2University of British Columbia,
Vancouver, BC; 3British Columbia Cancer
Agency, Victoria, BC
95 TREATMENT AND OUTCOMES OF PATIENTS WITH
King Tan1, Cheryl Alexander2, Randy
Gascoyne1, Joseph Connors1 1British
Cheryl Alexander , Joycelin Canavan ,
Caroline Speers2, Ivo Olivotto3 1British
3
MELANOMA: DO THEY CORRELATE? Rolina AlWassia, Fabricio Gonclaves, Crystal Holly,
Jeffry Chankowsky, George Shenouda
McGill University Health Centre, Montreal, QC
89ARE THERE PATIENT SUBSETS WITH NODE-
NEGATIVE BREAST CANCER THAT MAY BENEFIT
FROM REGIONAL NODAL RT? A POPULATIONBASED ANALYSIS OF WOMEN WITH MA20–
DEFINED “HIGH-RISK, NODE-NEGATIVE” BREAST
CANCER Pauline Truong1, Scott Tyldesley2,
94MRI AND US IN THE FOLLOW-UP OF CHOROIDAL
100PILOT DOSIMETRIC STUDIES OF INTENSITY
MODULATED VERSUS 3D-CONFORMAL
RADIOTHERAPY FOR LOCALLY ADVANCED NONSMALL CELL LUNG CANCER (LA-NSCLC) Lindsay
Mathew, Jack Skozny, Joe Szabo, Orest
Ostapiak, James Wright, Gordon Okawara,
Ranjan Sur, Anand Swaminath, Thomas
Corbett Tsakiridis, Theodoros Tsakiridis
Juravinski Cancer Centre, Hamilton, ON
Toronto, ON
THURSDAY September 13 CARO 2012
11
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
101PREDICTING SYMPTOMATIC RADIATION
PNEUMONITIS AFTER CONCURRENT
CHEMORADIOTHERAPY FOR NON-SMALL CELL
LUNG CANCER: RESULTS OF AN INTERNATIONAL
INDIVIDUAL PATIENT DATA META-ANALYSIS David
106THE CHARACTERISTICS OF CERVICAL LYMPH
NODE RESOLUTION FOLLOWING PRIMARY
RADIOTHERAPY +/- CHEMOTHERAPY FOR N2-N3
HEAD AND NECK CANCER Sophie Huang1,
Brian O’Sullivan1, Wei Xu1, Helen Zhao1,
Duo-Duo Chen2, Kelvin Chan1, Andrew
Hope1, John Kim1, Jolie Ringash1, Laura A
Dawson1, Andrew Bayley1, BC John Cho1,
David Goldstein1, Ralph Gilbert1, John N
Waldron1 1University of Toronto, Toronto, ON;
Palma , Suresh Senan , Kayoko Tsujino ,
Robert Barriger4, Ramesh Rengan5, Marta
Moreno6, Jeffrey Bradley7, Tae Hyun Kim8,
Sara Ramella9, Lawrence Marks10, Luigi
De Petris11, Larry Stitt1, George Rodrigues1
1
2
3
London Regional Cancer Program, London,
ON; 2VU University Medical Center, Amsterdam,
Netherlands; 3Hyogo Cancer Center, Hyogo,
Japan; 4Indiana University School of Medicine,
Indianapolis, IN; 5University of Pennsylvania,
Philadelphia, PA; 6Clínica Universidad de
Navarra, Pamplona, Spain; 7Washington
University School of Medicine, St. Louis, MO;
8
National Cancer Center, Goyang, Korea;
9
Campus Bio-Medico University, Rome, Italy;
10
University of North Carolina, Chapel Hill,
NC; 11Karolinska University Hospital Solna,
Stockholm, Sweden
Princess Margaret Cancer Centre, Toronto, ON
1
2
107CAN RADIOLOGICAL CHANGES DURING
TREATMENT PREDICT SUCCESS OF RADIATION
THERAPY IN PATIENTS WITH LOCALLY ADVANCED
HEAD AND NECK SQUAMOUS CELL CARCINOMA
(HNSCC)? Sanju Mishra, Alexander
Hammond, Nancy Read, Varagur
Venkatesan, Eric Winquist, Anthony
Nichols, David Palma University of Western
Ontario, London, ON
102DELINEATION VARIABILITY ON PLANNING CT
AND CONE-BEAM CT WHEN CONTOURING
THE BLADDER AS AN ORGAN-AT-RISK Tara
Rosewall1, Jason Xie2, Andrew Bayley1,
Peter Chung1, Geoffrey Currie3, Janelle
Wheat3, Michael Milosevic1 1University of
Toronto, Toronto, ON; 2Princess Margaret Cancer
Centre, Toronto, ON; 3Charles Sturt University,
Wagga Wagga, New South Wales, Australia
Hussain AlHussain, Alain Haddad, Saif AlThaqfi, Samy El-Sayed, Robert Zohr, Yves
Deshaies, Kathy Carty, Jason Belec, Ionut
Busca University of Ottawa, Ottawa, ON
104IS PERCENTAGE OF WEIGHT LOSS PREDICTIVE
OF THE NEED FOR RE-PLANNING OF PATIENTS
WITH HEAD AND NECK SQUAMOUS CELL
CARINOMA (HNSCC) TREATED WITH INTENSITYMODULATED RADIOTHERAPY (IMRT)? RESULTS OF
A PROSPECTIVE STUDY Joel Broomfield, Samy
El-Sayed, Hussain AlHussain, Ionut Busca,
Stacy Yemchuk, Jamie Bahm University of
Ottawa, Ottawa, ON
105THE INCIDENCE OF TREATMENT MODIFICATION
BASED ON DAILY CONE BEAM CT ASSESSMENT
FOR HEAD AND NECK CANCER PATIENTS Carla
Cerase, James Loudon, Brian O’Sullivan,
John Kim, John Waldron, Laura Dawson,
Stephen Breen Princess Margaret Cancer
SQUAMOUS CELL CARCINOMAS OF THE HEAD AND
NECK: POPULATION BASED OUTCOMES FROM A
CANADIAN PROVINCE Robert Olson1, Frances
Wong2, Jonn Wu1, John Hay1 1University
of British Columbia, Vancouver, BC; 2British
Columbia Cancer Agency, Fraser Valley Centre,
Surrey, BC
109QUALITY OF LIFE OUTCOMES WITH COMBINED
SPARING OF PAROTID AND SUBMANDIBULAR
GLANDS IN HEAD AND NECK IMRT Rufus
Scrimger1, Hadi Seikaly2, Matthew
Parliament2, Lisa Capelle2, Jeffrey Harris2,
David Williams2, Naresh Jha2 1Cross Cancer
103DOSIMETRIC COMPARISONS BETWEEN THREE-
DIMENSIONAL CONFORMAL RADIOTHERAPY
(3D-CRT) AND INTENSITY MODULATED RADIATION
THERAPY USING HELICAL TOMOTHERAPY (HT)
IN PATIENTS WITH HEAD AND NECK SQUAMOUS
CELL CARCINOMA (HNSCC) Joel Broomfield,
108 TWENTY-FIVE YEAR SURVIVAL OUTCOMES FOR
Institute, Edmonton, AB; 2University of Alberta,
Edmonton, AB
110EVALUATION OF SKIN DOSE DISTRIBUTION IN
HEAD AND NECK CANCER PATIENTS REQUIRING
RADIATION THERAPY WITH COVERAGE OF THE
TRACHEOSTOMY SITE Julia Skliarenko,
Ananth Ravi, Justin Lee University of Toronto,
Toronto, ON
111MCGILL EXPERIENCE WITH HEAD AND NECK
RE-IRRADIATION Rolina Al-Wassia1, Siavosh
Vakilian1, Crystal Holly2, Khalil Sultanem1,
George Shenouda2 1McGill University,
Montreal, QC; 2McGill University Health Centre,
Montreal, QC
112CORRELATION OF NECK NODAL LEVELS WITH THE
RISK OF DISTANT METASTASIS IN PATIENTS WITH
HEAD AND NECK SQUAMOUS CELL CARCINOMA
Hussain Al Hussain, Ionut Busca, Samy
El-Sayed, Libni Eapen University of Ottawa,
Ottawa, ON
Centre, Toronto, ON
THURSDAY September 13 CARO 2012
12
CARO • ACRO ANNUAL SCIENTIFIC MEETING
113TUMOUR CONTROL AND COSMETIC OUTCOMES
OF ORTHOVOLTAGE RADIOTHERAPY FOR MEDIAL
CANTHAL BASAL CELL CARCINOMAS Evelyn
SEPTEMBER 12 – 15, Ottawa, ON
119ONLINE OPTIMIZATION OF RADIOTHERAPY
PATIENT SCHEDULING Antoine Legrain1,
Marie-Andree Fortin2, Nadia Lahrichi1,
Louis-Martin Rousseau1 1Ecole Polytechnique
Herrmann, H Krema, David Payne, Rand
Simpson, Normand Laperriere, Caroline
Chung Princess Margaret Cancer Centre,
Toronto, ON
114PREDICTORS OF RADIOTHERAPY FAILURE IN NON
de Montreal, Montreal, QC; 2Universite de
Montreal, Montreal, QC
120OPTIMAL SCHEDULING OF RADIATION THERAPISTS
BASED ON PATIENT, STAFF AND ORGANIZATIONAL
CONSIDERATIONS John French, Vincent
MELANOMA SKIN CANCER Luluel Khan, Dale
Breen, Lying Zhang, Judith Balogh, Greg
Czarnota, Justin Lee, May Tsao, Elizabeth
Barnes University of Toronto, Toronto, ON
115ELECTRON THERAPY FOR NON-MELANOMA
SKIN CANCERS: COMPUTER SIMULATED
BOLUS VERSUS ACTUAL PHYSICAL BOLUS
FOR TREATMENT PLANNING Darwin Yip,
Chow, Pablo Santibanez, Martin Puterman,
Scott Tyldesley University of British Columbia,
Vancouver, BC
121FROM DATA TO KNOWLEDGE – CREATING A
PROVINCIAL PERFORMANCE METRICS SYSTEM
BY USING DATA CONTAINED WITHIN THE ARIA
PRODUCTION DATABASE John French, Vincent
Greg Salomons, Gary Bracken, Michael
Brundage Queen’s University, Kingston, ON
116ARE WEB-BASED RESOURCES THE BREAST?
AN EVALUATION OF THE QUALITY OF ONLINE
RESOURCES FOR BREAST CANCER PATIENTS
Chow, Pablo Santibanez, Martin Puterman,
Scott Tyldesley University of British Columbia,
Vancouver, BC
122RADIOTHERAPY RESOURCES IN AFRICA: AN IAEA
UPDATE ON THE CURRENT STATUS AND NEEDS
Paris-Ann Ingledew1, Baljeet Brar2, Julia
Lin2, Glenn Regehr2, Sonia Kim Anh
Nguyen1 1University of British Columbia,
Jean-Marc Bourque1, May Abdel-Wahab2,
Ed Rosenblatt2, Debbie Van der Merwe2,
Yaroslav Pynda2, Joanna Izewska2, Ahmed
Meghzifene2 1London Regional Cancer
Surrey, BC; 2University of British Columbia,
Vancouver, BC
117CONTINUITY CLINICS IN ONCOLOGY TRAINING
PROGRAMS IN CANADA Jennifer Croke1,
Program, London, ON; 2International Atomic
Energy Agency, Vienna, Austria
Michael Vickers2, Daniel Heng2, Martin
Reaume3, Xinni Song3, Joanne Meng3,
Tim Asmis3, Catherine Lochrin3, Choan
E3 1University of Ottawa, Ottawa, ON; 2Tom
123GLOBAL HEALTH IN POSTGRADUATE MEDICAL
EDUCATION: RESULTS OF A NATIONAL SURVEY
AND A LITERATURE REVIEW Jean-Marc
Bourque1, Mark Masterson2, Keren
Mandelzweig3, Gabe Boldt11 University of
Baker Cancer Centre, Calgary, AB; 3The Ottawa
Hospital, Ottawa, ON
118REDUCING PATIENT WAIT TIMES FOR RADIATION
THERAPY AND IMPROVING RADIATION
TREATMENT PLANNING EFFICIENCY WITH THE
AID OF A DISCRETE-EVENT SIMULATION MODEL
Western Ontario, London, ON; 2University of
Bristish Columbia, Vancouver, BC; 3University of
Manitoba, Winnipeg, MB
124A PHASE II STUDY OF AN INFORMATIONAL DVD TO
Inge Aivas1, Vusal Babashov1, Mehmet
Begen1, Michael Lock1, Jeffrey Cao2,
Derrick Fournier1, David D’Souza1, George
Rodrigues1, Greg Zaric1 1University of
ENHANCE CLINICAL TRIAL ACCRUAL IN BREAST
CANCER PATIENTS Heidi Wong, Catherine
Ennis, Alan Nichol, Lorna Weir, Scott
Tyldesley, Mira Keyes, Hannah Carolan,
Christina Aquino-Parsons University of
British Columbia, Vancouver, BC
Western Ontario, London, ON; 2University of
British Columbia, Vancouver, BC
4:45–6:15
Annual General Meeting
6:15–7:30
Reception Ottawa Convention Centre, Level 2
Facilitators: Andrea Bezjak, Board of Directors
THURSDAY September 13 CARO 2012
13
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
Friday September 14, 2012
6:30–7:30
CROF Fun Run/Walk Meet in Hotel Lobby at 6:15 am
7:30–8:50
Breakfast and Registration Level 2
AWARD WINNERS AND SPONSORS MEET AND GREET Room 201
8:50–9:00
Welcome and Introductions Gatineau Salon
Jason Pantarotto, Mary Gospodarowicz
9:00–10:00
Gordon Richards Lecture
Next-Gen Radiation Oncology Fei-Fei Liu
10:00–11:00 Poster
Viewing Ottawa Salon
11:00–12:30 Canadian
Brachytherapy Group Session Gatineau Salon
Moderator: Boris Bahoric
11:00–11:50 Canadian
Brachytherapy Group Keynote
HDR MONOTHERAPY FOR PROSTATE CANCER: SUCCESS WITHOUT EXTERNAL
BEAM RADIOTHERAPY? Mihai Ghilezan
11:50–12:00 125URINARY TOXICITY DECLINE IN 2011 PROSTATE BRACHYTHERAPY PATIENTS WITH LONG
TERM FOLLOW UP; BRITISH COLUMBIA PROVINCIAL PROSTATE BRACHYTHERAPY PROGRAM
OUTCOMES Elisa K Chan, Mira Keyes, Tom Pickles, Vincent Lapointe, Ingrid
Spadinger, Michael Mckenzie, W James Morris British Columbia Cancer Agency,
Vancouver, BC
12:00–12:10 126
MRI GUIDED HIGH DOSE RATE VAGINAL INTERSTITIAL BRACHYTHERAPY FOR LOCALLY
RECURRENT VAGINAL CANCERS Nikhilesh Patil, George Hajdok, Gail McBrayne,
Kathleen Surry, Akira Sugimoto, Michel Prefontaine, Leanne Derrah, Tammie
Murray, Andrea Lum, David D’Souza University of Western Ontario, London, ON
12:10–12:20 127
OPTIMAL OUTCOME AFTER PERMANENT SEED PROSTATE BRACHYTHERAPY: THE TRIFECTA
ANALYSIS Audrey Tetreault-Laflamme1, Thomas Zilli2, Guila Delouya1, Daniel
Taussky1 1Centre Hospitalier de l’Université de Montréal, Montreal, QC ; 2Hôpital
Universitaire de Genève, Genève, Switzerland
12:20–12:30 128MRI-GUIDED BRACHYTHERAPY PROCESS FOR CERVICAL CANCER: IDENTIFY PROCEDURE TIME
& OPPORTUNITIES FOR EFFICIENCIES Kitty Chan1, Tara Rosewall2, Brenda Kenefick2,
Mike Milosevic2 1Princess Margaret Cancer Centre, Toronto, ON; 2University of Toronto,
Toronto, ON
12:30–1:30 CANADIAN BRACHYTHERAPY GROUP ANNUAL GENERAL MEETING Gatineau Salon
Facilitator: Boris Bahoric
12:30–2:30 Lunch – on your own
FRIDAY September 14 CARO 2012
14
CARO • ACRO ANNUAL SCIENTIFIC MEETING
Workshops
WORKSHOP 1 Room 201
ADJUVANT THERAPY FOR ENDOMETRIAL CANCER
Facilitator: Ida Ackerman
2:30–4:00
SEPTEMBER 12 – 15, Ottawa, ON
OBJECTIVES: At the end of this session the learner will:
❚ appreciate the pros and cons of adjuvant radiotherapy for endometrial
cancer using cases as illustration;
❚ understand the controversies and potential role of adjuvant
chemotherapy for endometrial cancer;
❚ understand the potential advantages and disadvantages of IMRT for
adjuvant pelvic radiotherapy.
WORKSHOP 2 Room 203
QUALITY IN A RADIATION PROGRAM
Facilitator: Glenn Jones
OBJECTIVES: At the end of this session the learner will:
❚ have criteria to identify, map and align activities and points of
information exchange or interaction within a cancer program across a
clinical trajectory;
❚ rebalance Quality of Decisions Treatment and Life;
❚ describe infrastructures supporting and sustaining a Quality-based
clinical program;
❚ apply this method to one’s own loco-regional context.
WORKSHOP 3 Room 204
LUNG SBRT – BEYOND THE OBVIOUS
Facilitators: Andrea Bezjak, Patrick Cheung, Rob MacRae, David Palma, Anand
Swaminath
OBJECTIVES: At the end of this session the learner will:
❚ become aware of different ways in which centres deal with SBRT lung
for lesions that is very close to a critical organ at risk;
❚ reflect on the clinical and technical issues that may make a patients
with early stage NSCLC not a candidate for SBRT;
❚ have a better understanding of the issues related to evaluation of
radiological response after lung SBRT;
❚ consider what type of patient with oligometastatic disease would be
suitable for treatment with lung SBRT.
WORKSHOP 4 Room 103
LEADERSHIP WORKSHOP: DEVELOPING LEADERS OF EXCELLENCE, SUCCESSION PLANNING AND
MENTORING THE LEADERS OF TOMORROW
Facilitators: Chandra Martens, Peter Craighead, Michael Lock, Ross Halperin, Padraig
Warde, Woodrow Wells, Ethan Lyn, Mary Gospodarowicz
OBJECTIVES: At the end of this session the learner will:
❚ hear from current key leaders and experts who have an understanding
of, and practical tools, to mentor and to develop both new and existing
leaders in our Oncology centres;
❚ enhance succession planning, leadership development, and
encourage team building and positive working relationships between
multidisciplinary teams working together;
❚ be given practical advice and tools from the key medical leaders, based
on experience and research in succession planning, and have these
tools available to apply in their own centres.
FRIDAY September 14 CARO 2012
15
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
WORKSHOP 5 Room 104
IMAGE-GUIDED BRACHYTHERAPY “BEYOND THE SEED”
Facilitators: Juanita Crook, Gerard Morton, Jean-Philippe Pignol, Té Vuong
OBJECTIVES: At the end of this session the learner will:
❚ be aware of the use of image guidance in the delivery of brachytherapy
that expands indications into new and exciting territory;
❚ be familiar with patient selection, technical aspects and physics
considerations in situations such as guided breast seed brachytherapy,
US-guided interstitial HDR gyne brachytherapy, US planned DHR
prostate brachytherapy and ano-rectal HDR Brachytherapy.
Oral Session 1 Room 205/207
CLINICAL – BREAST AND HEAD AND NECK
2:30–2:40
129IDENTIFICATION OF PATIENTS AT VERY LOW RISK OF LOCAL RECURRENCE AFTER BREAST
2:40–2:50
130
RADIOTHERAPY IN THE TREATMENT OF LUMINAL A BREAST CANCER: IMPACT ON HEALTH CARE
2:30–4:00
Moderator: Alia Norman
OBJECTIVES: ❚ To review Breast Cancer recurrence risks and how to mitigate these risks.
❚ To review outcomes in the treatment of Head and Neck Cancers.
CONSERVING SURGERY AND RADIATION Sally Smith, Pauline Truong, Mary Lesperance,
Linghong Lu, Ivo Olivotto University of British Columbia, Victoria, BC
COST IN CANADA Mei Ling Yap1, Jean Yong2, Jeffrey Hoch1, Eric Gutierrez3, Padraig
Warde1, Anthony Fyles1, Fei-Fei Liu1 1University of Toronto, Toronto, ON; 2Canadian
Centre for Applied Research in Cancer Control, Toronto, ON; 3Cancer Care Ontario, Toronto, ON
2:50–3:00
131
MULTIFOCAL/MULTICENTRIC BREAST CANCER IS ASSOCIATED WITH INCREASED LOCAL
RECURRENCE Tiffany Tam, Shelly Hayes, Tianyu Li, Lori Goldstein, Marcia Boraas,
Richard Bleicher, Elin Sigurdson, Paula Ryan, Penny Anderson Fox Chase Cancer
Center, Philadelphia, PA
3:00–3:10
132
MATURE CLINICAL RESULTS OF A PROSPECTIVE CLINICAL TRIAL EVALUATING INTENSITY
MODULATED RADIATION THERAPY BY TOMOTHERAPY (IMRT-HT) FOR LOCO REGIONAL BREAST
RADIATION Jean-Michel Caudrelier, Bernd Esche, Joanne Meng, Lynn Montgomery,
Liz O’Neil, Laval Grimard Ottawa Hospital Regional Cancer Centre, Ottawa, ON
3:10–3:20
133
NODAL AID: A NOVEL DYNAMIC ANATOMIC LEARNING ATLAS FOR IMPROVING DELINEATION
IN THE RADIOTHERAPY TREATMENT PLANNING OF ADVANCED BREAST CANCERS Robert
Dinniwell1, Grace Lee1, Michael Lock2 1University of Toronto, Toronto, ON; 2University of
Western Ontario, London, ON
3:20–3:30
134
LOCAL RECURRENCE RISK IN WOMEN WITH STAGE I BREAST CANCER IS DECLINING OVER TIME
Joycelin Canavan1, Pauline Truong1, Sally Smith1, Linghong Lu2, Mary Lesperance2,
Ivo Olivotto2 1British Columbia Cancer Agency, Vancouver Island, Victoria, BC; 2University of
Victoria, Victoria, BC
3:30–3:40
135
OUTCOME OF INTENSITY-MODULATED RADIATION THERAPY FOR HYPOPHARYNGEAL CANCER
3:40–3:50
136PATTERNS OF FAILURE IN PATIENTS TREATED WITH INTENSITY MODULATED RADIATION THERAPY
COMPARED TO CONVENTIONAL RADIOTHERAPY Isabelle Gauthier, Gary Mok, Haiyan
Jiang, Shao Hui Huang, Kelvin Chan, Ian J Witterick, Brian O’Sullivan, John N
Waldron, Andrew J Bayley, John B Cho, Bernard J Cummings, Laura A Dawson,
Andrew J Hope, John J Kim, Jolie Ringash Princess Margaret Cancer Centre, Toronto, ON
(IMRT) USING HELICAL TOMOTHERAPY (HT) FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA
(HNSCC), RESULTS OF A PROSPECTIVE TRIAL Hussain Al Hussain, Ionut Busca, Kathy
Carty, Joel Broomfield, Samy El-Sayed, Libni Eapen, Bernd Esche, Laval Grimard
University of Ottawa, Ottawa, ON
3:50–4:00
137DOES THE TIMING OF POST-RT PET-CT AFFECT ITS RELIABILITY IN PREDICTING TREATMENT
OUTCOMES OF HEAD AND NECK SQUAMOUS CELL CARCINOMA: A RETROSPECTIVE ANALYSIS OF
THE BRITISH COLUMBIA CANCER AGENCY EXPERIENCE, 2005–2010 Hosam Kader1, Leanne
Dickau1, Tarnjit Parhar2, Pete Tonseth2, Francois Benard2, Sally Smith1, Cheryl
Alexander1, John Hay2, Don Wilson2 1British Columbia Cancer Agency, Victoria, BC;
British Columbia Cancer Agency, Vancouver, BC
2
FRIDAY September 14 CARO 2012
16
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
4:00–4:30
Break
4:30–6:00
Oral Session 2 Room 206/208
CLINICAL – PROSTATE
OBJECTIVES: To review prostate cancer treatment outcomes.
4:30–4:40
138 PATIENT DECISION AIDS HELP EARLY-STAGE PROSTATE CANCER PATIENTS Deb Feldman-
Moderator: William Foster
Stewart1, Michael Brundage1, Christine Tong1, Rob Siemens1, Shabbir Alibhai2,
Tom Pickles3, John Robinson4 1Queen’s University, Kingston, ON; 2University Health
Network, Toronto, ON; 3British Columbia Cancer Agency, Vancouver, BC; 4University of
Calgary, Calgary, AB
4:40–4:50
139
WHO DIES FROM PROSTATE CANCER? AN ANALYSIS OF THE SEER DATABASE Scott Morgan,
Rodney Breau, Wayne Kendal University of Ottawa, Ottawa, ON
4:50–5:00 140
PROGNOSTIC VALUE OF CIRCULATING TUMOUR CELLS IN PROSTATE CANCER PATIENTS
ACURAUNDERGOING ADJUVANT OR SALVAGE RADIATION THERAPY Tracy Sexton1, Lori Lowes2,
Alison Allan2 1London Regional Cancer Program, London, ON; 2University of Western
Ontario, London, ON
5:00–5:10
141
A RANDOMIZED PHASE III STUDY OF SHORT TERM HORMONAL THERAPY AND DOSE ESCALATED
5:10–5:20
142
IMPACT OF NEOADJUVANT ANDROGEN DEPRIVATION ON FIDUCIAL MARKER MIGRATION IN
RADIATION THERAPY FOR LOCALIZED PROSTATE CANCER Rachel Glicksman, Gary Mok,
Jenna Sykes, Andrew Bayley, Peter Chung, Robert Bristow, Mary Gospodarowicz,
Charles Catton, Michael Milosevic, Padraig Warde University of Toronto, Toronto, ON
EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER Daniel Taussky, Jean-François
Carrier, Marie-Claude Beauchemin, Thu Van Nguyen, Dominic Béliveau-Nadeau,
David A Tiberi Université de Montréal, Montreal, QC
5:20–5:30 143
THE PROSTATE CANCER RISK STRATIFICATION (PROCARS) PROJECT: DATABASE CONSTRUCTION
ACURAAND OUTCOME ANALYSIS George Rodrigues1, Sandra Gonzalez-Maldonado2, Himu
Lukka3, Padraig Warde4, Michael Brundage5, Luis Souhami6, Juanita Crook7,
Fabio Cury8, Charles Catton4, Gary Mok4, Andre-Guy Martin9, Eric Vigneault10,
Jim Morris11, Tom Pickles11 1University of Western Ontario, London, ON; 2University of
Waterloo, Waterloo, ON; 3McMaster University, Hamilton, ON; 4University of Toronto, Toronto,
ON; 5Queen’s University, Kingston, ON; 6McGill University, Montreal, QC; 7British Columbia
Cancer Agency, Kelowna, BC; 8McGill University, Montreal, QC; 9Universite Laval, Laval, QC;
10
Universite Laval, Laval, QC, 11University of British Columbia, Vancouver, BC
5:30–5:40
144
THE PROSTATE CANCER RISK STRATIFICATION (PROCARS) PROJECT: RECURSIVE PARTITIONING
ACURARISK STRATIFICATION ANALYSIS George Rodrigues1, Sandra Gonzalez-Maldonado2,
Himu Lukka3, Padraig Warde4, Michael Brundage5, Luis Souhami6, Juanita Crook7,
Fabio Cury8, Charles Catton4, Gary Mok4, Andre-Guy Martin9, Eric Vigneault10,
Jim Morris11, Tom Pickles11 1University of Western Ontario, London, ON; 2University of
Waterloo, Waterloo, ON; 3McMaster University, Hamilton, ON; 4University of Toronto, Toronto,
ON; 5Queen’s University, Kingston, ON; 6McGill University, Montreal, QC; 7British Columbia
Cancer Agency, Kelowna, BC; 8McGill University, Montreal, QC; 9Universite Laval, Laval, QC;
10
Universite Laval, Laval, QC, 11University of British Columbia, Vancouver, BC
5:40–5:50 145
POPULATION-BASED 10 YEAR EVENT-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR
ACURAPATIENTS WITH PROSTATE CANCER IN BRITISH COLUMBIA Scott Tyldesley, Jill Quirt, William
Morris, Micheal Peacock, Alan So, Charmaine Kim-Sing, Tom Pickles University of
British Columbia, Vancouver, BC
5:50–6:00
146DOES PHOENIX FAILURE DEFINITION APPLY TO EBRT + HDR BRACHYTHERAPY BOOST IN
PROSTATE CANCER? André-Guy Martin, Eric Vigneault, Sylviane Aubin, Nicolas
Varfalvy, Luc Beaulieu, Philippe Despré L’Hôtel-Dieu de Québec, Quebec, QC
FRIDAY September 14 CARO 2012
17
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
Oral Session 3 Room 205/207
TECHNOLOGY
4:30–6:00
Moderator: Cynthia Araujo, David Bowes
OBJECTIVES:
❚ To review Quality Assurance issues in Radiation Oncology.
❚ To review Stereotactic Radiotherapy in Canada: past outcomes, present
scope of practice and future planning issues.
4:30–4:40
147PEER-REVIEW OF RADIATION TREATMENT PLANNING ACTIVITIES IN A PROVINCIAL RADIATION
ONCOLOGY PROGRAMME: A SURVEY OF CURRENT PRACTICE Michael Brundage1, Sophie
Foxcroft2, Tom McGowan3, Michael Sharpe4, Eric Gutierrez5, Padraig Warde4
Cancer Centre of Southern Ontario, Kingston, ON; 2Princess Margaret Cancer Centre,
Toronto, ON; 3Credit Valley Hospital, Mississauga, ON; 4University of Toronto, Toronto, ON;
5
Cancer Care Ontario, Toronto, ON
1
4:40–4:50
148
PHYSICIAN REVIEW AND QA OF CONTOURS DRAWN FOR RADICAL RADIOTHERAPY Marco
Carlone, Glenn Jones, Gaylene Medlam, Tom McGowan Credit Valley Hospital,
Mississauga, ON
4:50–5:00
149
A PROSPECTIVE STUDY TO DETERMINE INTEROBSERVER VARIABILITY OF GTV WITH FDG-
PET-CT COMPARED TO CT ALONE IN STAGE III NON-SMALL CELL LUNG CANCER USING 3D
ANALYSIS David Peterson1, Bashir Bashir2, Shahida Ahmed2, Sandor Demeter2, Amit
Chowdhury2, Boyd McCurdy2, Ryan Rivest2, Zoann Nugent2, Pam Brechin2, Naseer
Ahmed2 1Cancer Care Manitoba, Winnipeg, MB; 2University of Manitoba, Winnipeg, MB
5:00–5:10
150
IDENTIFYING AND MITIGATING RISK IN AFTER HOURS RADIATION TREATMENT DELIVERY Crystal
Angers, Julie Renaud, Brenda Clark Ottawa Hospital Cancer Centre, Ottawa, ON
5:10–5:20
151
DOES THE APPLICATION OF FAILURE MODE AND EFFECTS ANALYSIS IDENTIFY AND REDUCE RISK
FOR A TOMOTHERAPY TREATMENT PROCESS? Jamie Bahm, Ryan Studinski, Daniel La
Russa, Kathy Carty, Danielle Fraser, Lesley Buckley, Crystal Angers, Brenda Clark
University of Ottawa, Ottawa, ON
5:20–5:30
152
LUNG, LIVER, AND SPINE STEREOTACTIC BODY RADIOTHERAPY (SBRT): CANADIAN ASSOCIATION
OF RADIATION ONCOLOGY (CARO) SCOPE OF PRACTICE GUIDELINES Arjun Sahgal1,
David Roberge2, Devin Schellenberg3 Tom Purdie1, Anand Swaminanth4, Jason
Pantarotto5, Edith Filion2, Zolt Gabos6, Jim Butler7, Daniel Letourneau1, Giuseppina
Masucci2, Liam Mulroy8, Andrea Bezjak1, Laura Dawson1, Matthew Parliament6
University of Toronto, Toronto, ON; 2University of Montreal, Montreal, QC; 3University of
British Columbia, Vancouver, BC; 4McMaster University, Hamilton, ON; 5University of Ottawa,
Ottawa, ON; 6University of Alberta, Edmonton, AB; 7University of Manitoba, Winnipeg, MB;
8
Dalhousie University, Halifax, NS
1
5:30–5:40
153
TECHNOLOGY RESOURCE PLANNING IN RADIATION ONCOLOGY: AN APPLICATION OF A
NEEDS BASED ANALYTICAL FRAMEWORK TO RADIOSURGERY PLANNING IN ONTARIO Jeffrey
Greenspoon, Daria O’Reilly, Anthony Whitton, James Wright, Jonathan Sussman,
Stephen Birch McMaster University, Hamilton, ON
5:40–5:50
154
ESTIMATING THE NEED FOR STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR LUNG
ELEKTACANCER: AN EVIDENCE-BASED EPIDEMIOLOGIC APPROACH Jeffrey Cao1, Devin
Schellenberg2, Islam Mohamed3, Chad Lund2, Alexander Louie4, David Palma4,
George Rodrigues4, Robert Olson1, Scott Tyldesley11University of British Columbia,
Vancouver, BC; 2University of British Columbia, Surrey, BC; 3University of British Columbia,
Kelowna, BC; 4University of Western Ontario, London, ON
5:50–6:00
155
PITUITARY ADENOMAS TREATED WITH FRACTIONATED STEREOTACTIC RADIOTHERAPY: CLINICAL
OUTCOME AND TOXICITY Richard Tsang1, Houman Pebdani1, Nikhilesh Patil1, Idara
Edem2, Alisha Albert-Green1, Monique van Prooijen1, Mostafa Heydarian1, Shenaz
Ladak1, Gelareh Zadeh1, James Brierley1 1University of Toronto, Toronto, ON; 2Queen’s
University, Toronto, ON
6:45
Dinner and Awards Ceremony
Museum of Civilization–Canada Hall, 100, rue Laurier Street, Gatineau
Transportation provided from the Westin to the Museum and back.
First bus leaves at 6:30pm.
FRIDAY September 14 CARO 2012
18
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
Saturday September 15, 2012
7:15–8:00
Breakfast and Registration
7:30–9:00
Workshops
WORKSHOP 1 Room 201
ADJUVANT THERAPY FOR ENDOMETRIAL CANCER
Facilitator: Ida Ackerman
OBJECTIVES: At the end of this session the learner will:
❚ appreciate the pros and cons of adjuvant radiotherapy for endometrial
cancer using cases as illustration;
❚ understand the controversies and potential role of adjuvant
chemotherapy for endometrial cancer;
❚ understand the potential advantages and disadvantages of IMRT for
adjuvant pelvic radiotherapy.
WORKSHOP 2 Room 203
QUALITY IN A RADIATION PROGRAM
Facilitator: Glenn Jones
OBJECTIVES: At the end of this session the learner will:
❚ have criteria to identify, map and align activities and points of
information exchange or interaction within a cancer program across a
clinical trajectory;
❚ rebalance Quality of Decisions Treatment and Life;
❚ describe infrastructures supporting and sustaining a Quality-based
clinical program;
❚ apply this method to one’s own loco-regional context.
WORKSHOP 3 Room 204
LUNG SBRT – BEYOND THE OBVIOUS
Facilitators: Andrea Bezjak, Patrick Cheung, Rob MacRae, David Palma, Anand
Swaminath
OBJECTIVES: At the end of this session the learner will:
❚ become aware of different ways in which centres deal with SBRT lung
for lesions that is very close to a critical organ at risk;
❚ reflect on the clinical and technical issues that may make a patients
with early stage NSCLC not a candidate for SBRT;
❚ have a better understanding of the issues related to evaluation of
radiological response after lung SBRT;
❚ consider what type of patient with oligometastatic disease would be
suitable for treatment with lung SBRT.
WORKSHOP 4 Room 103
LEADERSHIP WORKSHOP: DEVELOPING LEADERS OF EXCELLENCE, SUCCESSION PLANNING AND
MENTORING THE LEADERS OF TOMORROW
Facilitators: Chandra Martens, Peter Craighead, Michael Lock, Ross Halperin, Padraig
Warde, Woodrow Wells, Ethan Lyn, Mary Gospodarowicz
OBJECTIVES: At the end of this session the learner will:
❚ hear from current key leaders and experts who have an understanding
of, and practical tools, to mentor and to develop both new and existing
leaders in our Oncology centres;
❚ enhance succession planning, leadership development, and
encourage team building and positive working relationships between
multidisciplinary teams working together;
❚ be given practical advice and tools from the key medical leaders, based
on experience and research in succession planning, and have these
tools available to apply in their own centres.
SATURDAY September 15 CARO 2012
19
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
8:00–9:00
Canadian Brachytherapy Group Session Room 206/208
Moderator: Gerard Morton
OBJECTIVES: To review selected Canadian brachytherapy practices and outcomes.
8:00–8:10
156
VALIDATION STUDY OF US-BASED HDR PROSTATE BRACHYTHERAPY PLANNING COMPARED TO
CT GOLD STANDARD Juanita Crook, Deidre Batchelar, Matt Schmid, Cynthia Araujo,
Marie-Pierre Milette, David Petrik, Francois Bachand, Miren Gaztanaga University of
British Columbia, Kelowna, BC
8:10–8:20
157 IMAGE GUIDED ADAPTIVE BRACHYTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER -
RESULTS OF A MULTIINSTITUTIONAL DATA COLLECTION Alina Sturdza1, Lars Urlich Fokdal2,
Jacob Christian Lindegaard2, Karen Nkiwane1, Christian Kirisits1, Kari Tanderup2,
Richard Pötter1, RetroEMBRACE Study Group3 1Medical University of Vienna, Vienna,
Austria; 2Aarhus University, Aarhus University, Denmark; 3Multi-institutional, Vienna, Paris,
Aarhus, Leuven, London, Ljubljana, Cambridge, Dublin, Chiang Mai, Mumbay, Utrecht, Austria
8:20–8:30 158 A CANADIAN SURVEY OF INTRAUTERINE CERVIX BRACHYTHERAPY FROM A PHYSICS
PERSPECTIVE Kristin Marchant, Evgeny Sadikov University of Saskatchewan, Regina, SK
8:30–8:40
159
INTEGRATION OF CT-PLANNED INTERSTITIAL BRACHYTHERAPY BOOST IN ADVANCED
GYNECOLOGIC MALIGNANCIES Ericka Wiebe1, Kathleen Surry2, Nikhilesh Patil3, Simran
Aulakh2, Frances Whiston2, Larry Stitt2, David D’Souza3 1Odette Cancer Centre,
Toronto, ON; 2University of Western Ontario, London, ON; 3London Regional Cancer Program,
London, ON
8:40–8:50
160ULTRASOUND-CT FUSION COMPARED WITH MR-CT FUSION FOR POST-IMPLANT DOSIMETRY
IN PERMANENT PROSTATE BRACHYTHERAPY David Bowes1, Juanita Crook2, Cynthia
Araujo2, Miren Gaztanago2, Deidre Batchelar2 1Nova Scotia Cancer Agency, Halifax, NS;
British Columbia Cancer Agency, Kelowna, BC
2
8:50–9:00
161
THE LONG TERM EXPERIENCE OF PERMANENT SEED IMPLANT MONOTHERAPY IN LOW AND
9:00–10:30
Oral Session 4 Room 206/208
EDUCATION AND SURVIVORSHIP
Moderators: Chandra Martens, Zahra Kassam
OBJECTIVES: To review educational, supportive care and survivorship issues for both
Radiation Oncology professionals and their patients.
9:00–9:10
162
THE IMPACT OF UNDERGRADUATE EDUCATION IN RADIATION ONCOLOGY Ravinder Pandher,
INTERMEDIATE RISK PROSTATE CANCER Eric Vineault, Ag Martin, W Foster, S Aubin, P
Després, Luc Beaulieu CHUQ, Quebec, QC
Theresa Trotter University of Calgary, Calgary, AB
9:10–9:20
163RADIATION ONCOLOGY RESIDENT WORKLOAD IN A CANADIAN PROVINCE: ANALYSIS OF NEW
9:20–9:30
164
THE UNIVERSITY OF TORONTO RADIATION ONCOLOGY FELLOWSHIP PROGRAM: A SURVEY OF
PATIENT AND FOLLOW UP DICTATION DATA Eric Tran, Hannah Carolan, Robert Olson
British Columbia Cancer Agency, Vancouver, BC
FELLOWS BETWEEN 1998-2008 Max Dahele1, Zahra Kassam2, Mary Gospodarowicz2,
Elena Gessas2, Charles Catton2 1VU University Medical Center, Amsterdam, Netherlands;
University of Toronto, Princess Margaret Cancer Centre, Toronto, ON
2
9:30–9:40
165
TRAINING THE “COMPLETE RADIATION ONCOLOGIST”: INSTRUCTIONAL METHODS USED FOR
CANMEDS TRAINING IN CANADIAN RADIATION ONCOLOGY PROGRAMS Paris-Ann Ingledew1,
Chandra Martens2, Tamara Shenkier3, Sonia Kim Anh Nguyen1 1University of British
Columbia, Surrey, BC; 2McGill University, Gatineau, QC; 3University of British Columbia,
Vancouver, BC
9:40–9:50
166MEETING THE INFORMATIONAL NEEDS OF ONCOLOGY PATIENTS THROUGH THE INNOVATIVE USE
OF INFORMATION TECHNOLOGY – ARE WE READY YET? Larry Pan, Gwen MacDonald, Judy
Hale, Liz Dobbin, Ethan Laukkanen PEI Cancer Treatment Centre, Charlottetown, PE
9:50–10:00
167
RESULTS OF A CLUSTER RANDOMIZED TRIAL OF AN EARLY NURSING INTERVENTION TO
IMPROVE SUPPORIVE CARE FOR BREAST AND COLORECTAL CANCER PATIENTS Jonathan
Sussman1, Daryl Bainbridge2, Doris Howell3 1Juravinski Cancer Centre, Hamilton, ON;
McMaster University, Hamilton, ON; 3University of Toronto, Toronto, ON
2
SATURDAY September 15 CARO 2012
20
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
10:00–10:10 168
PALLIATIVE RADIOTHERAPY (RT) IN PATIENTS WITH POOR PERFORMANCE STATUS - SHOULD WE
TAILOR OUR TREATMENT? Chris Fosker, Tony Panzarella, Shawde Harris, Anthea Lau,
Michelle Lau, Corsita Garraway, Michael McLean, Wilfred Levin, Andrea Bezjak,
Rebecca KS Wong Princess Margaret Cancer Centre, Toronto, ON
10:10–10:20 169CHILDHOOD CANCER SURVIVORS’ PERSPECTIVES AND PREFERENCES FOR LONG-TERM MEDICAL
FOLLOW-UP Karen Goddard1, Rob Olson1, Gabe Hung2, Fuchsia Howard2 1British
Columbia Cancer Agency, Vancouver, BC; 2University of British Columbia, Vancouver, BC
10:20–10:30 170
HEALTH INDICATORS IN THE RADIOTHERAPY WORKPLACE Geneviève Coulombe,
Dominique Lefebvre, Daniel Payette, Michèle De Guise, Danielle Daunais, Amélie
Ouellette, Jean-Pierre Guay, David Roberge CHUM, Montréal, QC
Oral Session 5 Room 205/207
CLINICAL – LUNG AND CNS
Facilitator: Holly Campbell
OBJECTIVES: To review response to radiation and treatment outcomes in selected
Canadian cancer centres.
9:00–9:10
171A PHASE II STUDY OF ACCELERATED HYPOFRACTIONATED 3-DIMENSIONAL CONFORMAL
9:00–10:40
RADIOTHEARPY FOR INOPERABLE T1-3 N0 M0 NON-SMALL CELL LUNG CANCER: NCIC CTG
BR.25 Patrick Cheung1, Sergio Faria2, Shahida Ahmed3, Pierre Chabot4, Jonathan
Greenland5, Elizabeth Kurien6, Islam Mohamed7, James Wright8, Keyue Ding9,
Chris O’Callaghan9 1Odette Cancer Centre, Toronto, ON; 2McGill University, Montreal, QC;
Cancer Care Manitoba, Winnipeg, MB; 4Hopital Maisonneuve-Rosemont, Montreal, QC;
Dr. H. Bliss Murphy Cancer Centre, St John’s, NL; 6Tom Baker Cancer Centre, Calgary, AB;
7
British Columbia Cancer Agency, Kelowna, BC; 8Juravinski Cancer Centre, Hamilton, ON;
9
Queen’s University, Kingston, ON
3
5
9:10–9:20
172 DIFFERENTIATING RADIATION FIBROSIS FROM TUMOUR RECURRENCE AFTER STEREOTACTIC
ABLATIVE RADIOTHERAPY (SABR) FOR LUNG CANCER: THE IMPACT OF CT-BASED IMAGE
TEXTURE ANALYSIS Sarah Mattonen1, Aaron D Ward1, Cornelis JA Haasbeek2 Suresh
Senan2, David Palma3 1University of Western Ontario, London, ON; 2VU University Medical
Center, Amsterdam, Netherlands; 3London Regional Cancer Program, London, ON
9:20–9:30
173NTCP MODELING OF RADIOGRAPHIC CHANGES IN NORMAL LUNG TISSUE IN PATIENTS TREATED
WITH CONVENTIONAL AND HYPOFRACTIONATED RADIATION THERAPY David Palma1, Quentin
Diot2, Suresh Senan3, Michael Lawrence4, Soren Bentzen5, Brian Kavanagh2,
Lawrence Marks4, Moyed Miften2 1London Regional Cancer Program, London, ON;
University of Colorado School of Medicine, Aurora, CO; 3VU University Medical Center,
Amsterdam, Netherlands; 4University of North Carolina, Chapel Hill, NC; 5University of
Wisconsin, Madison, WI
2
9:30–9:40
174
METFORMIN ENHANCES RADIATION RESPONSES IN NON-SMALL CELL LUNG CANCER (NSCLC)
RAZCER
Yaryna Storozhuk1, Sarah Hopmans1, Toran Sanli1, Carly Barron2, Evangelia Tsiani2,
Carrie Thomas Farrell3, Schultz3, Jean-Claude Cutz1, Robert Bristow4, James
Wright1, Gurmit Singh1, Theodoros Tsakiridis1 1McMaster University, Hamilton, ON;
Brock University, St. Catharines, ON; 3Juravinski Cancer Centre, Hamilton, ON; 4University of
Toronto, Toronto, ON
2
9:40–9:50
175
LUNG TUMOUR TRACKING: LESSONS LEARNED TREATING OUR FIRST 200 CYBERKNIFE PATIENTS
Houda Bahig, Edith Filion, Marie-Pierre Campeau, Robert Doucet, Dominic
Béliveau Nadeau, Louise Lambert, Toni Vu, David Roberge Centre Hospitalier de
l’Université de Montréal, Montréal, QC
9:50–10:00
176
A RANDOMIZED COMPARISON OF LUNG STEREOTACTIC BODY RADIATION THERAPY (SBRT)
DELIVERED OVER 4 OR 11 DAYS – ACUTE TOXICITY AND QUALITY OF LIFE Suneil Jain1,
Patrick Cheung1, Ian Poon1, Brian Keller1, Hany Soliman2, Fiona Lochray1 1Odette
Cancer Centre, Toronto, ON; 2Carlo Fidani Peel Regional Cancer Centre, Mississauga, ON
10:00–10:10 177 C ORRELATION OF HIGH-GRADE GLIOMA RELAPSE VOLUMES WITH RADIOTHERAPY TARGET
VOLUMES DELINEATED USING 18F-FDOPA PET TRACER UPTAKE Elisa K Chan1, Robert
Kosztyla1, Fred Hsu2, Don Wilson1, Roy Ma1, Arthur Cheung2, Vitali Moiseenko1,
Susan Zhang1, Francois Benard1, Alan Nichol1 1British Columbia Cancer Agency,
Vancouver, BC; 2British Columbia Cancer Agency, Abbotsford, BC
SATURDAY September 15 CARO 2012
21
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
10:10–10:20 178 FINAL RESULTS OF A PROSPECTIVE TRIAL EVALUATING ACCELERATED RADIATION THERAPY
USING TOMOTHERAPY SIMULTANEOUS INTEGRATED BOOST (ARTOSIB) WITH CONCURRENT
AND ADJUVANT TEMOZOLOMIDE (TMZ) CHEMOTHERAPY IN THE TREATMENT OF GLIOBLASTOMA
MULTIFORME (GBM) Jean-Michel Caudrelier1, Hussain AlHussain1, Shawn Malone2,
Stan Gertler1, Thanh Nguyen2, Garth Nicholas1, Nancy Page1, John Woulfe2,
Olugesun Agboola1, Lynn Montgomery 1Ottawa Hospital Regional Cancer Centre, Ottawa,
ON; 2The Ottawa Hospital, University of Ottawa, ON
10:20–10:30 179
BOOST VERSUS SALVAGE RADIOSURGERY FOR BRAIN METASTASES AFTER WHOLE BRAIN
RADIOTHERAPY Fred Hsu1, Sonia Nguyen2, Arthur Cheung2, Michael McKenzie3, Roy
Ma3, Alan Nichol3 1British Columbia Cancer Agency, Abbotsford, BC; 2British Columbia
Cancer Agency, Surrey, BC; 3British Columbia Cancer Agency, Vancouver, BC
10:30–10:40 180
PHASE I DOSE ESCALATION STUDY OF SUNITINIB AND RADIOSURGERY FOR BRAIN METASTASES
Caroline Chung, Cynthia Ménard, Christiaan Stevens, Normand Laperriere,
Barbara-Ann Millar, Mark Bernstein, Gelareh Zadeh, Warren Mason, Anthony
Brade University of Toronto, Toronto, ON
10:30–11:00 Break
11:00–12:30 CARO-ESTRO
Symposium Gatineau Salon
FRONTIERS IN RADIATION BIOLOGY: THE NEXT DECADE
Moderators: Andrea Bezjak, Fabio Cury
OBJECTIVES: To provide an interactive symposium addressing clinical application of
targeted therapy from the European and Canadian viewpoint.
CHALLENGES AND OPPORTUNITIES IN DEVELOPING RT AND TARGETED THERAPY PROTOCOLS
Donal Hollywood
INTEGRATING GENOMICS INTO CLINICAL PRACTICE Robert Bristow
Case/Panel Discussion Panelists: Donal Hollywood, Robert Bristow, Anne Hansen Ree
12:30–12:45 Break
12:45–2:00
People’s Choice Gatineau Salon
Moderator: Ross Halperin
OBJECTIVES: To highlight exemplary Canadian-led research in Radiation Oncology.
12:45–1:00
181
RADIUM-223 CHLORIDE (ALPHARADIN) IMPROVES OVERALL SURVIVAL Shawn Malone, E
Leung, Libni Eapen, J Garcia-Vargas, Chris Parker University of Ottawa, Ottawa, ON
1:00–1:15
182PHASE II TRIAL OF NEO-ADJUVANT TEMOZOLOMIDE (TMZ) FOLLOWED BY CONCURRENT TMZ
AND HYPOFRACTIONATED ACCELERATED EXTERNAL BEAM RADIOTHERAPY (AC-EBRT) AND
ADJUVANT TMZ FOR PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM): PRELIMINARY
RESULTS George Shenouda, Luis Souhami, Valerie Panet-Raymond, Bassam
Abdulkarim, Fabio Cury, Scott Owen, Kevin Petrecca, Marie-Christine Guiot, Petr
Kavan, Rolando DelMaestro, Richard Leblanc McGill University, Montreal, QC
1:15–1:30
183
POST-MENOPAUSAL WOMEN WITH LUMINAL A SUBTYPE MIGHT NOT REQUIRE BREAST
RADIOTHERAPY – PRELIMINARY RESULTS FROM A RANDOMIZED CLINICAL TRIAL OF TAMOXIFEN
+ RADIATION Lorna Weir1, Anthony Fyles2, Willa Wei Shi3, Melania Pintilie2, Susan
Done2, Naomi Miller2, Derek Wong3, Ivo Olivotto4, Maureen Trudeau5, David
McCready2, Fei-Fei Liu2 1British Columbia Cancer Agency, Vancouver, BC; 2Princess
Margaret Cancer Centre, Toronto, ON; 3Ontario Cancer Institute, Toronto, ON; 4British
Columbia Cancer Agency, Victoria, BC; 5Odette Cancer Centre, Toronto, ON
1:30–1:45
184
THE IMPACT OF RADIOTHERAPY (RT) ON QUALITY OF LIFE (QOL) WHEN GIVEN IN COMBINATION
WITH ANDROGEN DEPRIVATION THERAPY (ADT) FOR LOCALLY ADVANCED PROSTATE CANCER:
QOL RESULTS FROM NCIC CTG PR3 / MEDICAL RESEARCH COUNCIL MRC PR07 RANDOMIZED
TRIAL Michael Brundage1, Wendy Parulekar2 Bingshu Chen2, Andrea Bezjak3,
Matthew Sydes4, Malcom Mason5, Andrea Hiltz2, Padraig Warde3 1Cancer Centre
of Southern Ontario, Kingston, ON; 2NCIC CTG, Kingston, ON; 3Princess Margaret Cancer
Centre, Toronto, ON; 4MRC Clinical Trials Unit, London, United Kingdom;5Cardiff University
School of Medicine, Cardiff, United Kingdom
SATURDAY September 15 CARO 2012
22
CARO • ACRO ANNUAL SCIENTIFIC MEETING
1:45–2:00
SEPTEMBER 12 – 15, Ottawa, ON
185
FINAL ANALYSIS OF INTERGROUP RANDOMIZED PHASE III STUDY OF ANDROGEN DEPRIVATION
THERAPY (ADT) +/- RADIATION THERAPY (RT) IN LOCALLY ADVANCED PROSTATE CANCER
(NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633) Padraig Warde1, Wendy
Parulekar2, Max Parmar3, John Anderson4, John Barber5, Michael Brundage6,
Bingshu Chen2, Richard Cowan7, Mary Gospodarowicz1, Charles Hayter8, John
Hetherington9, Andrea Hiltz2, Peter Kirkbride4, Edward Kostashuk10, Karen
Sanders3, Jinka Sathya11, Gregory Swanson12, Mathew Sydes3, Malcolm Mason13
Princess Margaret Cancer Centre, Toronto, ON; 2NCIC CTG, Kingston, ON; 3MRC Clinical
Trials Unit, London, United Kingdom; 4Weston Park Hospital, Sheffield, United Kingdom;
5
Velindre Hospital, Cardiff, United Kingdom;6Kingston Regional Cancer Centre , Kingston, ON;
7
Christie Hospital, Manchester, United Kingdom; 8Carlo Fidani Cancer Centre, Mississauga,
ON; 9Castle Hill Hospital, Hull, United Kingdom; 10Fraser Valley Cancer Centre, Surrey, BC;
11
H Bliss Murphy Cancer Clinic, St John’s, NL; 12University of Texas Health Sciences Center,
San Antonio, TX; 13Cardiff University, Cardiff, United Kingdom
1
2:00
Closing Remarks Ross Halperin, Chandra Martens
SATURDAY September 15 CARO 2012
23
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
POSTER ABSTRACTS
186ADJUVANT RADIOTHERAPY IMPROVES LOCAL CONTROL AND SURVIVAL IN PATIENTS WITH UTERINE
ELEKTA LEIOMYOSARCOMA Philip Wong, Kathy Han, Jenna Sykes, Charles Catton, Stephane
Laframboise, Anthony Fyles, Lee Manchul, Wilfred Levin, Michael Milosevic University of
Toronto, Toronto, ON
187GRADE OF TOXICITY IN IMMUNOSUPPRESSED PATIENTS FOLLOWING RADIATION THERAPY FOR PRIMARY
HEAD AND NECK CANCER Rania Hashem, Fabio Cury, McGill, Karen Kost, Anthony Zeitouni,
George Shenouda McGill University Health Centre, Montreal, QC
188
A METHODOLOGY FOR THE EARLY DETECTION OF NON-SMALL CELL LUNG CANCER USING MIRNA
PROFILING IN SPUTUM Wilson Roa1, Rene Razzak1, Hongfei Du2, Linghong Guo1, Ravinder
Singh1, Sayf Gazala3, Julian Kim1, Sunita Ghosh1, Eric Wong3, Eric Bedard3, James Xing3
Cross Cancer Institute, Edmonton, AB; 2University of Electronic Science and Technology, Chengdu,
Chengdu, China; 3University of Alberta, Edmonton, AB
1
189
OPTIMAL STRATEGY FOR PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED STAGE SMALL CELL LUNG
CANCER Patricia Tai1, Avi Assouline2, Kurian Joseph3, Edward Yu4 1Allan Blair Cancer Centre,
Regina, SK; 2Centre Clinique de la Porte de Saint Cloud, Boulogne, France; 3University of Alberta,
Edmonton, AB; 4University of Western Ontario, London, ON
190
SHOULD RADIATION THERAPY BE OFFERED TO NONAGENARIANS? Jean Archambault Université Laval,
Québec, QC
191
PILOT INTERDISCIPLINARY PALLIATIVE LUNG RAPID ACCESS RADIOTHERAPY CLINIC – EXPERIENCES,
PERCEPTIONS, AND GOALS Shilo Lefresne, Karen Levy, Rosemary Cashman, Robert Olson
British Columbia Cancer Agency, Vancouver, BC
192RELATIONSHIPS BETWEEN FAMILY PHYSICIANS TESTED KNOWLEDGE, SELF-PERCEIVED KNOWLEDGE,
AND UTILIZATION OF PALLIATIVE RADIOTHERAPY Robert Olson, Sonca Lengoc, John French,
Colleen McGahan, Scott Tyldesley, Jenny Soo British Columbia Cancer Agency, Vancouver, BC
193
IMPLEMENTATION AND EARLY EVALUATION OF LINAC IMRT FOR THE POST OPERATIVE LOCOREGIONAL
RADIATION OF BREAST CANCER Sara Samiee1, Manon Lacelle2, Balazs Nyiri3, Nicolas Ploquin2,
Jean-Michel Caudrelier2 1University of Ottawa, Ottawa, ON; 2Ottawa Hospital Cancer Centre,
Ottawa, ON; 3The Ottawa Hospital, Ottawa, ON
194
THE “CSRT EFFECT”: IMPLEMENTING ADVANCED PRACTICE INTO A BONE AND BRAIN METASTASES
CLINIC Julie Blain1, Laura Zychla1, Marcia Smoke1, Nicole Harnett2, William McMillan1
McMaster University, Hamilton, ON; 2University of Toronto, Toronto, ON
1
195
CLINICAL OUTCOMES AFTER SALVAGE RADIOSURGERY FOR BRAIN METASTASES Goldie Kurtz, Gelareh
Zadeh, Genevieve Gingras-Hill, Barbara-Ann Millar, Normand Laperriere, Mark Bernstein,
Cynthia Ménard, Caroline Chung University of Toronto, Toronto, ON
196SEED MIGRATION IN PROSTATE BRACHYTHERAPY DEPENDS ON EXPERIENCE AND TECHNIQUE Guila
Delouya, Daniel Taussky, Camille Moumdjian, Renée Larouche, Dominic BéliveauNadeau, Chantal Boudreau, Yannick Hervieux, David Donath CHUM-Hôpital Notre-Dame,
Montreal, QC
197PATTERNS OF FAILURE FOLLOWING INTRA-OPERATIVE PROSTATE BRACHYTHERAPY AT 8.5 YEARS USING
INTRA-OPERATIVE INVERSE PLANNING AND AN AUTOMATED DELIVERY SYSTEM Siraj Husain, Steve
Angyalfi, Michael Sia Tom Baker Cancer Centre, Calgary, AB
198
DIMINISHING BENEFITS OF BREATH HOLD TECHNIQUE WITH BREAST CONSERVING THERAPY Angela
Lin1, Waseem Sharieff1, Jim Whelan1, Joe Szabo2, Chris DiFranscisco2, Michelle
Finucane2, Julie Chase2, Do-Hoon Kim1 1McMaster University, Hamilton, ON; 2Juravinski Cancer
Centre, Hamilton, ON
199
INTERSTITIAL BRACHYTHERAPY AND LOCAL RESECTION FOR RECTAL CANCER IN 70 PATIENTS Laval
Grimard1, Hartley Stern2, Robin Boushey3 1The Ottawa Hospital Cancer Centre, Ottawa, ON,
McGill University, Montreal, QC, 3Université d’Ottawa, Ottawa, ON
2
200HYPOFRACTIONATION IN PROSTATE CANCER: LEARNING WHEN THE “SAME DOSE” CAN LEAD TO
DIFFERENT TOXICITY Sergio Faria, Luis Souhami, Russel Ruo, James Coates, Issam El Naqa
McGill University, Montreal, QC
POSTER ABSTRACTS CARO 2012
24
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
201
ROLE OF PALLIATIVE RADIATION THERAPY FOR SPINAL CORD COMPRESSION DUE TO METASTATIC
MALIGNANT MELANOMA Isabelle Thibault1, Marc Gaudet2, Philippe Després3, Anne Dagnault1
CHUQ, L’Hôtel-Dieu de Québec, Québec, QC; 2Hôpital de Gatineau, Gatineau, QC ; 3Université Laval,
Québec, QC
1
202IMPROVING WAIT TIMES FOR RADIOTHERAPY BY SHORTENING THE WAIT FOR SIMULATION VISITS
Monica Behl1, Sheila Coulter2, Diane Treppel3, Renee Belitski4 1Allan Blair Cancer Centre,
Regina, SK; 2Saskatoon Cancer Centre, Saskatoon, SK; 3Saskatchewan Cancer Agency, Saskatoon,
SK; 4Saskatchewan Cancer Agency, Regina, SK
203 CHOROIDAL METASTASES IN BREAST CANCER: OUTCOMES OF A POPULATION-BASED COHORT Jeffrey
ELEKTACao, Scott Tyldesley, Hannah Carolan, Ryan Woods, Caroline Speers, Robert Olson
University of British Columbia, Vancouver, BC
204EVALUATION OF DEFORMABLE REGISTRATION SOFTWARE FOR BIOLOGICALLY EQUIVALENT DOSE (BED)
SUMMATION AND ANALYSIS IN SPINE RE-IRRADIATION Anoop Haridass, Janet Hendry, Lesley
Buckley, Shawn Malone University of Ottawa, Ottawa, ON
205TREATMENT AND PLANNING CHALLENGES OF A DOSE ESCALATION TRIAL OF MULTIPLE MYELOMA
PATIENTS BY TREATING TOTAL MARROW USING TOMOTHERAPY Lynn Montgomery, Larry Atkins, Lee
Gerig, Kathy Carty, Gosia Niedbala, Balazs Nyiri, Rajiv Samant University of Ottawa, Ottawa, ON
206AN ELEGANT SOLUTION TO RTOG 0933 Joe Andreas, Vijayanda Kundapur, Gavin CranmerSargison University of Saskatchewan, Saskatoon, SK
207IMPACT OF RADICAL PROSTATECTOMY ON RECTAL POSITION AND IMPLICATIONS FOR CTV DEFINITION
FOR POST-OPERATIVE PROSTATE RADIATION Jennifer Croke1, Balazs Nyiri2, Len Avruch2, Eric
Belanger2, Chris Morash2, Shawn Malone2 1University of Ottawa, Ottawa, ON; 2The Ottawa
Hospital, Ottawa, ON
208
THE USE OF ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (ACGH) IN THE DEVELOPMENT OF
PERSONALIZED APPROACHES TO PROSTATE CANCER THERAPY Robert Bristow1, Adrian Ishkanian1,
Gaetano Zafarana1, Jennifer Locke2, Alice Meng2, Chad Maloff3, Wan Lam3, Michael
Fraser1, Colin Collins2, Stanislav Volik2, Lakshmi Muthuswamy4, John McPherson4,
Thomas Hudson4, Lincoln Stein4, Theodorus van der Kwast5, Paul Boutros4 1Princess
Margaret Cancer Centre, Toronto, ON; 2STTARR Innovation Program, Toronto, ON; 3STTARR
Innovation Program, Toronto, ON; 3University of British Columbia, Vancouver, BC; 4Ontario Institute for
Cancer Research, Toronto, ON; 5University Health Network, Toronto, ON
209
IS RADIATION THERAPY WITH CETUXIMAB AN EFFECTIVE TREATMENT IN HUMAN PAPILLOMA VIRUS
POSITIVE LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CANCER Allison Chew, Cheryl Ho,
Jonn Wu British Columbia Cancer Agency, Vancouver, BC
210
THE IMPACT OF RESPIRATORY GATING ON TOXICITY OUTCOMES FOR LOCALLY ADVANCED LUNG CANCER
TREATED WITH RADICAL CHEMORADIOTHERAPY Stephanie M Casey, Alexander V Louie, George
Rodrigues, David Palma, Brian Yaremko, A Rashid Dar, Edward Yu, Inge Aivas, Andrew
Warner, Stewart Gaede London Regional Cancer Program, London, ON
211STEREOTACTIC LUNG RADIOTHERAPY: OUTCOMES AND TOXICITY OF VARIOUS DOSE REGIMENS USED
AT THE MCGILL UNIVERSITY HEALTH CENTRE Lily Shakibnia1, Bassam Abdulkarim2, Issam El
Naqa2, Sergio Faria2, Neil Kopek2, Emily Soisson2, Jonathan Wan2 1McGill University Health
Centre, Montreal, QC; 2McGill University, Montreal, QC
212
IS THERE A DETRIMENT TO DELIVERING THORACIC RADIOTHERAPY OVER >19 DAYS IN LIMITED-STAGE
SMALL CELL LUNG CANCER? Eric Tran1, Cheryl Alexander2, Devin Schellenberg3, Elaine Wai2
British Columbia Cancer Agency, Vancouver, BC; 2British Columbia Cancer Agency, Victoria, BC;
British Columbia Cancer Agency, Surrey, BC
1
3
213OUTCOME OF STAGE I NON-SMALL CELL LUNG CANCER AFTER STEREOTACTIC BODY RADIATION
THERAPY, DOES GROWTH RATE MATTER? Soha Atallah, Andrea Bezjak, Mojgan Taremi, Zishan
Allibhai, Lisa Le, Alexander Sun, Anthony Brade, John Cho, Andrew J Hope University of
Toronto, Toronto, ON
214PHOTODYNAMIC THERAPY FOR BOWEN’S DISEASE OF THE PENIS Alexander Louie1, Justin Chia2,
Kevin Jordan1, Jim Gilchrist1, Barbara Fisher1, David D’Souza11London Regional Cancer
Program, London, ON; 2University of Western Ontario, London, ON
POSTER ABSTRACTS CARO 2012
25
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
215TRANSIENT TUMOUR VOLUME INCREASE IN VESTIBULAR SCHWANNOMAS AFTER RADIOTHERAPY Lara
Hathout1, Carole Lambert2, Jean-François Carrier2, Jean-Paul Bahary2, Yannick Hervieux2,
Robert Moumdjian2, Marie-Andrée Fortin2, David Roberge2 1Université de Montréal, Montreal,
QC ; 2Centre hospitalier de l’Université de Montréal, Montreal, QC
216
TECHNIQUE FOR USING DYNAMIC CT ANGIOGRAPHY (DCTA) FOR FRAMELESS STEREOTACTIC
RADIOSURGICAL (SRS) PLANNING OF INTRACRANIAL ARTERIO VENOUS MALFORMATIONS (AVM) Anoop
Haridass, Santanu Chakraborty, Robert Chatelain, Janos Szanto, Cheemun Lum, Shawn
Malone, John Sinclair The Ottawa Hospital, Ottawa, ON
217
FIDUCIAL MARKERS (FM) IN THE PROSTATE BED FOR POST PROSTATECTOMY EXTERNAL BEAM
RADIATION THERAPY: IMPROVED ACCURACY AS COMPARED TO THE USE OF SURGICAL CLIPS Israël
Fortin, Jean-François Carrier, Marie-Claude Beauchemin, Dominic Béliveau-Nadeau, Guila Delouya,
Daniel Taussky Université de Montréal, Montréal, QC
218
DOSIMETRY AND COST-EFFECTIVENESS COMPARATIVE ANALYSIS BETWEEN VOLUME MODULATED ARC
THERAPY (VMAT) AND HELICAL TOMOTHERAPY (HT) IN TREATMENT OF GLIOBLASTOMA MULTIFORME
(GBM) USING ACCELERATED RADIATION THERAPY WITH SIMULTANEOUS INTEGRATED BOOST (ARTOSIB)
Hussain Al Hussain, Robert Zohr, Jean-Michel Caudrelier, Shawn Malone University of
Ottawa, Ottawa, ON
219
“I’M NO TEACHER”: EXPLORING THE PERCEPTION OF RADIATION THERAPISTS IN ASSESSING CLINICAL
COMPETENCE OF UNDERGRADUATE STUDENTS WITHIN AN ACADEMIC CLINICAL SETTING Kieng
Tan1, Krista Dawdy2, Lisa Di Prospero1 1University of Toronto, Toronto, ON; 2Sunnybrook Health
Sciences Centre, Toronto, ON
220
RADIOTHERAPY FOR CERVIX CANCER: ARE WE REALLY IMPROVING OUTCOMES? Sofya Kobeleva1,
Rajiv Samant1, Choan E1, Khalid Balaraj2, Tien Le1, Michael Fung-Kee-Fung1 1University of
Ottawa, Ottawa, ON; 2Tawam Hospital, Al Ain, United Arab Emirates
221
RETROSPECTIVE COMPARISON OF TWO FEEDING TUBE APPROACHES FOR HEAD & NECK CANCER
PATIENTS RECEIVING CONCURRENT CHEMO-RADIATION THERAPY Irene Karam1, Gavin Wilson2,
Angela Bowman1, Frances Wong3, Robert Olson1 1British Columbia Cancer Agency, Vancouver,
BC; 2University of British Columbia, Vancouver, BC; 3British Columbia Cancer Agency, Fraser Valley
Centre, Surrey, BC
222
COMPARISON OF 3D CONFORMAL RADIOTHERAPY (3DCRT) AND INTENSITY MODULATED RADIOTHERAPY
(IMRT) IN STAGE III NON SMALL CELL LUNG CANCER (NSCLC) Paula McCloskey, Soha Atallah,
Linda Coate, Alisha Albert-Green, Tom Purdie, Andrew Hope, John Cho, Anthony Brade,
Alexander Sun, Frances Shepherd, Andrea Bezjak Princess Margaret Cancer Centre, Toronto, ON
223
BREAST CANCER SURVIVORSHIP CARE TAILORED TO SOUTH ASIAN WOMEN Sonia Kim Anh Nguyen1,
Savitri Singh-Carlson2, Frances Wong1 1British Columbia Cancer Agency, Fraser Valley Centre,
Surrey, BC; 2California State University, Long Beach, CA
224
BREAST CANCER CARE NAVIGATION IN RURAL SETTINGS: FEASIBILITY STUDY OF A SYSTEMS-LEVEL
APPROACH Dan Le1, Heather Wozney2, Robert Olson1 1University of British Columbia, Vancouver,
BC; 2University Hospital of Northern British Columbia, Prince George, BC
225
SUBCLINICAL MALIGNANT SPINAL CORD COMPRESSION – A MORE FAVORABLE ENTITY? Chris Fosker1,
Lisa Wang1, Shawde Harris2, Michelle Lau2, Wilfred Levin1, Michael McLean1, Andrea
Bezjak1, Raja Rampersaud2, Rebecca Wong1 1University of Toronto, Toronto, ON; 2Princess
Margaret Cancer Centre, Toronto, ON
226OPINIONS FROM THE EXPERTS: WHAT PROSTATE CANCER PATIENTS SHOULD KNOW ABOUT POSTOPERATIVE RADIOTHERAPY Laura D’Alimonte1, Deb Feldman-Stewart2, Arlene Court3,
Margaret Fitch3, Lisa Di Prospero3, John Maamoun3, Alex Kiss3, Ewa Szumacher3 1Odette
Cancer Centre, Toronto, ON; 2Queen’s University, Kingston, ON; 3University of Toronto, Toronto, ON
227
TANGLED IN THE BREAST CANCER WEB: AN EVALUATION OF THE USAGE OF WEB-BASED INFORMATION
RESOURCES BY BREAST CANCER PATIENTS Sonia Kim Anh Nguyen, Paris-Ann Ingledew British
Columbia Cancer Agency, Surrey, BC
228
CLINICAL OUTCOME OF PATIENTS WITH STAGE I ENDOMETRIAL CANCER: A SINGLE INSTITUTION
EXPERIENCE Saif Althaqfi, Rajiv Samant, Choan E, Krystine Lupe, Ian Bambury University of
Ottawa, Ottawa, ON
229
SUV STABILITY IN PRIMARY HEAD AND NECK CANCER: PRE- AND INTRA- TREATMENT FDG-PET/CT
ANALYSIS Tatiana Conrad, Benjiman Smith, Andrew Brotherston, Ian Poon University of
Toronto, Toronto, ON
POSTER ABSTRACTS CARO 2012
26
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
230
THE UTILIZATION OF IMRT PLANNING IN DECREASING THE RISK OF ACCELERATED DEMYELINATION IN
MULTIPLE SCLEROSIS PATIENTS FOLLOWING EXTERNAL BEAM RADIATION THERAPY Rania Hashem,
William Parker, Fabio Cury, Khalil Sultanem, William Tong, George Shenouda McGill
University Health Centre, Montreal, QC
231
MULTIDISCIPLINARY PREDICTION OF SURVIVAL IN ADVANCED CANCER PATIENTS Brock Debenham,
Brita Danielson, Fleur Huang, Sunita Ghosh, Alysa Fairchild University of Alberta, Edmonton, AB
232TEMPLATE-BASED BREAST IMRT PLANNING FOR INCREASED WORKLOAD EFFICIENCY Sonia Kim
Anh Nguyen, Fred Cao, Sarah Kristensen, Peter Steiner, Craig Elith, Winkle Kwan British
Columbia Cancer Agency, Surrey, BC
233
PERMANENT SEED BRACHYTHERAPY FOR LOCALLY RECURRENT PRSOTATE CANCER FOLLOWING
RADICAL PROSTATECTOMY: A CASE REPORT David Bowes1, Juanita Crook2, Miren Gaztanaga2
Nova Scotia Cancer Agency, Halifax, NS; 2British Columbia Cancer Agency, Kelowna, BC
1
234
4 D MONTE CARLO CALCULATIONS OF VMAT AND HELICAL TOMOTHERAPY DOSE DISTRIBUTIONS OF LUNG
STEREOTACTIC TREATMENTS WITH INTRA-FRACTION MOTION Jason Belec, Brenda Clark Carleton
University, Ottawa, ON
235
MULTIDISCIPLINARY MANAGEMENT OF CANCER PATIENTS: ARE WE CHASING OUR SHADOW OR ARE THEY
OF REAL VALUE? Jennifer Croke1, Samy El-Sayed2 1University of Ottawa, Ottawa, ON; 2The Ottawa
Hospital, Ottawa, ON
236
OMISSION OF A BOLUS IN POST-MASTECTOMY PATIENTS TREATED BY ADJUVANT RADIOTHERAPY:
RECURRENCE-FREE AND OVERALL SURVIVALS Melanie Letourneau1, Jean-Charles Hogue2,
Christine Desbiens2, Valérie Théberge1 1CHUQ, L’Hôtel-Dieu de Québec, Quebec, QC ; 2CHA
Universitaire de Québec, Pavillon St-Sacrement, Quebec, QC
237
RETROSPECTIVE ANALYSIS OF EARLY STAGE NON-SMALL CELL LUNG CANCER TREATED WITH AN
HYPOFRACTIONATED COURSE OF RADIATION THERAPY Marc-Emile Plourde, Michael Brundage,
Timothy Owen Queen’s University, Kingston, ON
238
MINIMAL CLINICALLY MEANINGFUL DIFFERENCE IN THE EORTC QLQ-C30 AND QLQ-BM22 IN PATIENTS
WITH BONE METASTASES Luluel Khan1, Liang Zeng1, Lying Zhang1, Ling-Ming Tseng2, MingFeng Hou3, Alysa Fairchild4, Vassilios Vassiliou5, Reynaldo Jesus-Garcia6, Mohamed A Alm
El-Din7, Rapid Response Radiotherapy Program8 1University of Toronto, Toronto, ON; 2National
Yang-Ming University, Taipei, Taiwan; 3Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;
4
Cross Cancer Institute, Edmonton, AB; 5Nicosia, Cyprus; 6Federal University of Sao Paulo, Sao Paulo,
Brazil; 7Tanta University Hospital, Tanta, Egypt; 8Odette Cancer Centre, Sunnybrook Health Sciences
Centre, University of Toronto, Toronto, ON
239
HER2 AND BASAL LIKE SUBTYPES OF INVASIVE BREAST CANCER ARE ASSOCIATED WITH A HIGHER
TUMOUR GRADE AND RATE OF LYMPH NODE METASTASIS Xingrao Wu McGill University, Montreal, QC
240
FOSTERING A NO-BLAME CULTURE: IMPLEMENTATION OF A LEARNING SERIES TO EDUCATE RADIATION
THERAPISTS ON THE QUALITY ASSURANCE PROGRAM AT A LARGE COMPREHENSIVE CANCER CENTRE
Brian Liszewski, Lisa Di Prospero, Anne Wighton University of Toronto, Toronto, ON
241
THE JUNIOR DOCTORS NETWORK OF THE WORLD MEDICAL ASSOCIATION: THE WORLD’S FIRST
INTERNATIONAL REPRESENTATIVE BODY FOR POSTGRADUATE MEDICAL TRAINEES Jean-Marc
Bourque1, Thorsten Hornung2, Adam Kaufman3, Lawrence Loh3, Rob Mitchell4, Will
Perry5, Xaviour Walker6 1London Regional Cancer Program, London, ON; 2Bonn University, Bonn,
Germany; 3University of Toronto, Toronto, ON; 4Australian Medical Association Council for Doctorsin-Training, St Barton, Australia; 5Harvard University, Cambridge, MA; 6Harvard Medical School,
Cambridge, MA
242
INVESTIGATION OF A THERMOPLASTIC MASK SYSTEM FOR HEAD AND NECK CANCER (HNC) RADIATION
THERAPY: DO FORMAL TRAINING SESSIONS FOR RADIATION THERAPISTS’ (RTS) IMPACT MASK FITTING
AND ISOCENTRE REPRODUCIBILITY? Angela Turner, Francois Gallant, Lisa DiProspero, Ananth
Ravi, Tammy Lui University of Toronto, Toronto, ON
243IS WEIGHT LOSS PREDICTIVE OF THE NEED FOR RE-PLANNING OF PATIENTS WITH HEAD AND NECK
CANCER TREATED WITH IMRT? A PROSPECTIVE STUDY Joel Broomfield, Stacey Yemchuk, Jamie
Bahm, Samy El-Sayed University of Ottawa, Ottawa, ON
POSTER ABSTRACTS CARO 2012
27
CARO • ACRO ANNUAL SCIENTIFIC MEETING
SEPTEMBER 12 – 15, Ottawa, ON
244
THE RELATIONSHIP BETWEEN THE OUTCOMES OF CLINICAL STAGE III NSCLC PATIENTS AND THE
PRACTICE PATTERNS OF PHYSICIANS: A TWO PROVINCE COHORT STUDY Hongwei Liu1, Benjamin
Mou2, Gerald Lim1, William M Hunter3, Zoann Nugent3, Ethan Lyn3, Harold Lau1 1Tom
Baker Cancer Centre, Calgary, AB; 2CancareCare Manitoba, Winnipeg, MB; 3CancareCare Manitoba,
Winnipeg, MB
245 MAKING SMARTPHONE PROGRAMMING ACCESSIBLE TO ALL: CREATING A CANCER STAGING APP USING
APP INVENTOR FOR ANDROID SMARTPHONES Derek S Tsang, Pamela Catton, James D Brierley
University of Toronto, Toronto, ON
246HEALTH RELATED QUALITY OF LIFE IN HEAD AND NECK CANCER TREATED WITH SURGERY WITH OR
WITHOUT RADIOTHERAPY OR CHEMORADIOTHERAPY Jonathan Livergant, Jonathan Klein, Jolie
Ringash University of Toronto, Toronto, ON
247
HEALTH RELATED QUALITY OF LIFE IN HEAD AND NECK CANCER TREATED WITH RADIATION THERAPY
WITH OR WITHOUT CHEMOTHERAPY University of Toronto, Toronto, ON
248
CUSTOMIZED VAGINAL VAULT BRACHYTHERAPY WITH CT IMAGING-DERIVED APPLICATOR PROTOTYPING
Ericka Wiebe, Gillian Thomas, Lisa Barbera, Harry Easton, Ananth Ravi Odette Cancer
Centre, Toronto, ON
249
THE PERCEPTION OF RADIATION THERAPY STUDENTS ON SITE-SPECIFIC TEACHING OF A CLINICAL
SPECIALIST RADIATION THERAPIST Grace Lee, Kieng Tan, Robert Dinniwell Princess Margaret
Cancer Centre, Toronto, ON
250
IMPLEMENTATION OF LUNG STEREOTACTIC ABLATIVE RADIOTHERAPY AT A REGIONAL CANCER CENTRE
Ravinder Pandher, Hong-Wei Lui, Rao Khan, Mona Udowicz, Yvette Bayliss, Krista
Krobutschek, Colleen Herring, Harold Lau University of Calgary, Calgary, AB
251
PURSUING THE METHODOLOGY TO COMPREHENSIVELY AND APPROPRIATELY EVALUATE THE UTILITY OF
EMERGING RADIATION THERAPY INNOVATIONS Hussain Al Hussain, Libni Eapen, Jean-Michel
Caudrelier University of Ottawa, Ottawa, ON
252
NEPHRON-SPARING ROBOTIC STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) USING CYBERKNIFE®
FOR MEDICALLY INOPERABLE PRIMARY RENAL TUMOURS AND TUMOURS ARISING FROM SOLITARY
KIDNEY: REPORT OF FEASIBILITY, TECHNIQUE, EFFICACY AND SAFETY Vimoj Janardanan Nair, Janos
Szanto, Eric Vandervoort, Ilias Cagiannos, Leonard Avruch, Jason Pantarotto, Shawn
Malone University of Ottawa, Ottawa, ON
253
A PRACTICAL AND OBJECTIVE SCORING METHOD FOR DOSIMETRIC COMPARISON OF INDIVIDUAL
STEREOTACTIC ABLATIVE RADIOTHERAPY TREATMENT PLANS Vimoj Janardanan Nair, Robert
MacRae, Nicolas Ploquin, Brenda Clark, Jason Pantarotto University of Ottawa, Ottawa, ON
254
ESTABLISHING A PLACE FOR AN ADVANCED PRACTICE RADIATION THERAPIST IN PALLIATIVE RADIATION
THERAPY: EXPERIENCES OF TWO URBAN CANCER CENTRES Emily Sinclair1, Michelle Lau2
University of Toronto, Toronto, ON; 2Princess Margaret Cancer Centre, Toronto, ON
1
255
ADJUVANT RADIATION THERAPY FOR METASTATIC SQUAMOUS CELL CANCER IN A PATIENT WITH
EPIDERMOLYSIS BULLOSA DYSTROPHICA: CASE STUDY AND LITERATURE REVIEW Theodora Koulis,
Colleen Herring, Jon-Paul Voroney Tom Baker Cancer Centre, Calgary, AB
256
EVALUATING ADJACENT ORGAN RADIATION DOSES FROM POST-OPERATIVE INTRACAVITARY VAGINAL
VAULT BRACHYTHERAPY FOR ENDOMETRIAL CANCER Julianna Caon1, Caroline Holloway2,
Rustom Dubash1, Conrad Yuen1, Christina Aquino-Parsons1 1British Columbia Cancer Agency,
Vancouver, BC; 2British Columbia Cancer Agency, Victoria, BC
257
A PILOT STUDY USED TO COMPARE THE ACUTE SIDE EFFECTS FROM EITHER PROSTATE BRACHYTHERAPY
LDR (SEED IMPLANT) PLUS EXTERNAL BEAM RADIOTHERAPY, OR HDR PROSTATE BRACHYTHERAPY
TREATMENT PLUS EXTERNAL BEAM RADIOTHERAPY Tracey Rose, Eleanor Garcia, Juanita Crook
British Columbia Cancer Agency, Kelowna, BC
POSTER ABSTRACTS CARO 2012
28
INNOVATIONS
IN IMAGING
ANNUAL SCIENTIFIC MEETING
CARO 2013
COMP Montreal, QC
September 18-21 • Hilton Bonaventure